Antigen binding proteins capable of binding thymic stromal lymphopoietin

Antigen-binding proteins targeting TSLP address the challenge of allergic and fibrotic disorders by inhibiting TSLP activity, offering therapeutic relief for conditions like asthma and atopic dermatitis.

JP2024161358AInactive Publication Date: 2024-11-19AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024111769
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2008-08-25
Filing Date
2024-07-11
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The increasing prevalence of allergic diseases and fibrotic disorders, such as asthma, allergic rhinitis, atopic dermatitis, and fibroproliferative diseases, is not effectively addressed by current anti-inflammatory treatments, as these mechanisms differ from those of inflammation, necessitating the development of TSLP antagonists to reduce and prevent fibrosis.

Method used

Development of antigen-binding proteins, including antibodies and fragments, that specifically bind to Thymic Stromal Lymphopoietin (TSLP) to inhibit its activity, thereby reducing inflammatory and fibrotic responses.

Benefits of technology

The antigen-binding proteins effectively inhibit TSLP activity, providing therapeutic benefits for allergic and fibrotic disorders by blocking TSLP signaling and reducing associated inflammation and fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161358000028
    Figure 2024161358000028
  • Figure 2024161358000029
    Figure 2024161358000029
  • Figure 2024161358000030
    Figure 2024161358000030
Patent Text Reader

Abstract

To provide compositions and methods relating to antigen binding proteins which include antibodies and bind to human thymic stromal lymphopoietin (TSLP).SOLUTION: The disclosure provides fully human, humanized, and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies, including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119 of U.S. Provisional Patent Application No. 61 / 091,676, filed August 25, 2008, and U.S. Provisional Patent Application No. 60 / 971,178, filed September 10, 2007, which are incorporated herein by reference.

[0002] FIELD OF THEINVENTION The field of the present invention is human thymic stromal lymphopoietin (THF) The present invention relates to compositions of antigen-binding proteins, including antibodies capable of binding to IgG1 lymphopoietin, and related methods. [Background technology]

[0003] 2. Background of the Invention The prevalence of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis and food allergies appears to have increased in recent years, especially in developed countries, with an increasing proportion of the affected population (Non-Patent Document 1). Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine produced in response to pro-inflammatory stimuli. TSLP has been found to promote allergic inflammatory responses primarily through its activity on dendritic cells and mast cells (Non-Patent Document 2, Non-Patent Document 3). Expression of human TSLP has been reported to be increased in asthmatic airways in correlation with disease severity (Non-Patent Document 4). In addition, TSLP protein levels are detectable in concentrated bronchoalveolar lavage (BAL) fluids of asthma patients and other patients suffering from allergic disorders. Increased levels of TSLP protein and mRNA are also found in the lesional skin of patients with atopic dermatitis (AD). Therefore, TSLP antagonists are useful in treating inflammatory disorders.

[0004] In addition, TSLP has also been found to promote fibrosis, as reported in US Patent Application No. 11 / 344,379. Fibrotic diseases occur when the fibrosis phase continues unchecked during tissue repair process, which leads to extensive tissue remodeling and the formation of permanent scar tissue (Non-Patent Document 5). It is estimated that up to 45% of deaths in the United States may be due to fibroproliferative diseases, which can affect many tissues and organ systems (Non-Patent Document 5).

[0005] Currently, anti-inflammatory treatments are used to treat fibrotic disorders. Because fibrosis is common in many persistent inflammatory diseases, such as idiopathic pulmonary fibrosis, progressive kidney disease and liver cirrhosis. However, the mechanisms involved in the control of fibrosis seem to be quite different from those of inflammation, and anti-inflammatory therapy is not always effective in reducing or preventing fibrosis (Non-Patent Document 5). Therefore, there remains a need to develop treatments that reduce and prevent fibrosis.

[0006] Thus, antagonists to TSLP are expected to be useful in treating these inflammatory and fibrotic disorders. The present disclosure provides such treatments and methods of treatment. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Kay, N Engl. J. Med. (2001) 344:30-37 [Non-Patent Document 2] Soumelis et al., Nat Immun (2002) 3(7):673-680 [Non-Patent Document 3] Allakhverdi et al., J.Exp.Med.(2007)204(2):253~258 [Non-Patent Document 4] Ying et al., J. Immunol. (2005) 174:8183~8190 [Non-Patent Document 5] Wynn, Nature Rev. Immunol. (2004) 4, 583. Summary of the Invention [Means for solving the problem]

[0008] Summary of the Invention In one aspect, the present disclosure provides an isolated antigen binding protein, the isolated antigen binding protein comprising: a. Below: i. a light chain CDR3 sequence that differs from a CDR3 sequence selected from the group consisting of light chain CDR3 sequences A1-A27 by a total of no more than two amino acid additions, substitutions, and / or deletions; ii. QQAX8SFPLT (SEQ ID NO: 251); and a light chain CDR3 sequence selected from b. Below: i. a heavy chain CDR3 sequence that differs from a CDR3 sequence selected from the group consisting of heavy chain CDR3 sequences A1-A27 by a total of no more than three amino acid additions, substitutions and / or deletions; ii. GGGIX 12 VADYYX 13 YGMDV (SEQ ID NO:255); iii.DX 21 GX 22 SGWPLFX 23 Y (sequence number 259) wherein X8 is an N residue or a D residue; 12 is a P or A residue; X 13 is a Y or F residue; X 21 is a G or R residue; X 22 is an S or T residue; X 23 is an A residue or a D residue, and the antigen binding protein specifically binds TSLP.

[0009] In another aspect, the isolated antigen binding protein of the present disclosure further comprises: a. Below: i. a light chain CDR1 sequence which differs from the light chain CDR1 sequences of A1-A27 by no more than 3 amino acid additions, substitutions and / or deletions; ii. RSSQSLX1YSDGX2TYLN (SEQ ID NO:246); iii. RASQX4X5SSWLA (SEQ ID NO: 249); A light chain CDR1 sequence selected from b. Below: i. a light chain CDR2 sequence which differs from the CDR2 sequences of A1-A27 by no more than two amino acid additions, substitutions and / or deletions; ii. KVSX3 (residues 1-4 of SEQ ID NO:247); iii. X6X7SSLQS (SEQ ID NO: 250); or iv. QDX9KRPS (SEQ ID NO: 252) a light chain CDR2 sequence selected from: c. Below: i. a heavy chain CDR1 sequence which differs from the CDR1 sequences of A1-A27 by no more than two amino acid additions, substitutions and / or deletions; ii.X 10 YGMH (SEQ ID NO: 253); iii.X 15 X 16 YMX 17 (SEQ ID NO:257); and a heavy chain CDR1 sequence selected from d. Below: i. a heavy chain CDR2 sequence which differs from the CDR2 sequences of A1-A27 by no more than 3 amino acid additions, substitutions and / or deletions; ii.VIWX 11 DGSNKYYADSVKG (SEQ ID NO: 254); iii.VISYDGSX 14 KYYADSVKG (SEQ ID NO: 256); iv.WINPNSGGTNX 18 X 19 X 20 KFQG (SEQ ID NO: 258); X1 is a V or I residue; X2 is an N or D residue; X3 is a Y or N residue; X4 is a G or S residue; X5 is an L or I residue; X6 is an N or T residue; X7 is a T or A residue; X9 is a K or N residue; 10 is an S or N residue; X 11 is a Y or F residue; X 14 is a Y or N residue; X 15 is a D or G residue; X 16 is a Y or D residue; X 17 is a Y or H residue; X 18 is a Y or H residue; X 19 is a V or A residue; X 20 is a Q or an R residue, and the antigen binding protein specifically binds TSLP.

[0010] In another aspect of the disclosure, the isolated antigen binding protein of claim 1 comprises: a. a light chain variable domain comprising: i. a light chain CDR1 sequence selected from A1-A27; ii. a light chain CDR2 sequence selected from A1-A27; iii. a light chain CDR3 sequence selected from A1-A27; or b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence selected from A1-A27; ii. a heavy chain CDR2 sequence selected from A1-A27; and iii. a heavy chain CDR3 sequence selected from A1-A27; or C. The light chain variable domain of (a) and the heavy chain variable domain of (b). Includes any of the following.

[0011] In a further aspect, the isolated antigen binding protein comprises: a. Below: i. an amino acid sequence having at least 80% identity to a light chain variable domain sequence selected from L1-L27; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding a light chain variable domain sequence of L1-L27; iii. A sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to a complement of a polynucleotide consisting of the light chain variable domain sequences L1 to L27; A light chain variable domain sequence selected from b. A heavy chain variable domain sequence selected from: i. a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence of H1-H27; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding a heavy chain variable domain sequence of H1-H27; iii. A sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to a complementary strand of a polynucleotide consisting of a heavy chain variable domain sequence of H1 to H27; or c. the light chain variable domain of (a) and the heavy chain variable domain of (b); wherein the antigen-binding protein specifically binds to TSLP.

[0012] In a further aspect, an isolated antigen binding protein of the present disclosure comprises either: a. a light chain variable domain sequence selected from L1-L27; b. a heavy chain variable domain sequence selected from H1-H27; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antigen binding protein specifically binds TSLP.

[0013] In a further aspect, the isolated binding protein is selected from the group consisting of L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13.1H13, L13.2H13, L14.1H14, L14.2H14, L15.1H15, L15.2H15, L16.1H16, and the like. , L16.2H16, L17H17, L18.1H18, L18.2H18, L19.1H19, L19.2H19, L20.1H20, L20.2H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26 and L27H27.

[0014] In a further aspect, the isolated antigen binding protein comprises a binding protein that binds to TSLP with a Kd substantially identical to a reference antibody selected from A2, A3, A4, and A5. In another aspect, the isolated antigen binding protein comprises a binding protein that inhibits TSLP activity with an IC50 according to a primary cell OPG assay identical to a reference antibody selected from A2, A3, A4, or A5.

[0015] In yet a further aspect, the isolated antigen-binding protein cross-competes with the reference antibody for binding to TSLP. In another aspect, the isolated antigen-binding protein binds to the same epitope as the reference antibody (e.g., A2, A4, A5, A6, A7, A10, A21, A23, or A26).

[0016] In one aspect, the isolated antigen binding protein is selected from a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single-chain antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an F(fa')x fragment, a domain antibody, an IgD antibody, an IgE antibody, and an IgM antibody, and an IgG1 antibody, and an IgG2 antibody, and an IgG3 antibody, and an IgG4 antibody, and an IgG4 antibody having at least one mutation in the hinge region that reduces the tendency to form intra-H chain disulfide bonds. In one aspect, the isolated antigen binding protein is a human antibody.

[0017] Also provided is an isolated nucleic acid molecule comprising a polynucleotide sequence encoding the light chain variable domain, the heavy chain variable domain, or both, of an antigen binding agent of the present disclosure. In one embodiment, the polynucleotide comprises light chain variable sequences L1-L27 and / or heavy chain variable sequences H1-H27, or both.

[0018] Also provided is a vector comprising the polynucleotide of the present disclosure. In one embodiment, the vector is an expression vector. Also provided is a host cell comprising the vector. Also provided is a hybridoma capable of producing the antigen binding protein of the present invention. Also provided is a method of making the antigen binding protein, comprising culturing the host cell under conditions that allow the host cell to express the antigen binding protein.

[0019] Also provided is a pharmaceutical composition comprising the antigen binding protein of the invention. In one embodiment, the pharmaceutical composition comprises a human antibody. Also provided is a method of treating a TSLP-associated inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition. In one embodiment, the inflammatory condition is The condition is allergic asthma, allergic rhinosinusitis, allergic conjunctivitis or atopic dermatitis. Also provided is a method of treating TSLP-associated fibrotic disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition. In one embodiment, the fibrotic disorder is scleroderma, interstitial lung disease, idiopathic pulmonary fibrosis, fibrosis resulting from chronic hepatitis B or chronic hepatitis C, radiation-induced fibrosis, and fibrosis resulting from wound healing. [Brief description of the drawings]

[0020] [Figure 1A] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 1B] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 1C] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 1D] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 1E] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 1F] The amino acid sequences of the light chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided. Additionally, exemplary nucleotide sequences encoding each CDR are provided. [Figure 2A] The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. [Figure 2B]The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. [Figure 2C] The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. [Figure 2D] The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. [Figure 2E] The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. [Figure 2F] The amino acid sequences of the heavy chain CDR1, CDR2 and CDR3 regions of A1-A27 are provided, as well as exemplary nucleotide sequences encoding each CDR. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] Detailed Description of the Invention The present invention relates to antigen binding agents (including antigen binding proteins) that specifically bind to the cytokine human thymic stromal lymphopoietin (TSLP), including antigen binding proteins that inhibit TSLP binding and signaling, such as antagonistic TSLP antibodies, antibody fragments, and antibody derivatives. These antigen binding agents are useful in inhibiting or blocking the binding of TSLP to its receptor and are useful in treating inflammatory diseases, fibrotic diseases, and other related conditions.

[0022] The invention further provides compositions, kits and methods relating to antigen binding proteins that bind TSLP. Nucleic acid molecules, including polynucleotide sequences encoding all or a portion of a polypeptide that binds TSLP, such as nucleic acids encoding all or a portion of an anti-TSLP antibody, antibody fragment, or antibody derivative, and derivatives and fragments thereof, are also provided. The invention further provides vectors and plasmids containing such nucleic acids, and cells or cell lines containing such nucleic acids and / or vectors and plasmids. Methods provided include, for example, methods for making, identifying or isolating antigen binding proteins that bind human TSLP (e.g., anti-TSLP antibodies), methods for determining whether an antigen binding protein is TSLP, and methods for determining whether an antigen binding protein is TSLP. The present invention also includes methods for determining whether an antigen binding protein that binds TSLP binds to TSLP, methods for making compositions (e.g., pharmaceutical compositions) comprising antigen binding proteins that bind TSLP, as well as methods for administering antigen binding proteins that bind TSLP to a subject (e.g., methods for treating a condition mediated by TSLP), and methods for modulating biological activity associated with TSLP signaling in vitro or in vivo.

[0023] TSLP Thymic stromal lymphopoietin (TSLP) refers to a four α-helical bundle type I cytokine that is a member of the IL-2 family, but is most closely related to IL-7. Cytokines are small regulatory proteins secreted in response to specific stimuli that act on receptors on the membranes of target cells. Cytokines regulate a variety of cellular responses. Cytokines are generally described in references such as Cytokines, edited by A. Mire-Sluis and R. Thorne, Academic Press, New York, (1998).

[0024] TSLP was originally cloned from a mouse thymic stromal cell line (Sims et al., J. Exp. Med 192(5), 671-680 (2000)) and found to support early B and T cell development. Later, human TSLP was cloned and found to have 43% amino acid sequence identity to the mouse homolog (Quentmeier et al., Leukemia 15, 1286-1292 (2001) and U.S. Patent No. 6,555,520, which is incorporated herein by reference). The polynucleotide and amino acid sequences of human TSLP are provided in SEQ ID NOs: 1 and 2, respectively. TSLP has been found to bind with low affinity to a receptor chain from the hematopoietin receptor family called the TSLP receptor (TSLPR) (SEQ ID NOs: 3 and 4), which is described in U.S. Patent Application Serial No. 09 / 895,945, Publication No. 2002 / 0068323). The polynucleotide sequence encoding human TSLPR is presented as SEQ ID NO: 3 of this application, and its amino acid sequence is presented as SEQ ID NO: 4 of this application, respectively. The soluble domain of TSLPR is approximately amino acids 25-231 of SEQ ID NO: 4. TSLP binds with high affinity to a heterodimeric complex of TSLPR and the interleukin 7 receptor alpha IL-7Rα (Park et al., J. Exp. Med 192:5 (2000), U.S. Patent Application Serial No. 09 / 895,945, Publication No. US2002 / 0068323). The sequence of IL-7 receptor alpha is shown in Figure 2 of U.S. Patent No. 5,264,416, which is incorporated herein by reference. The sequence of the soluble domain of IL-7 receptor alpha is amino acids 1-219 of Figure 2 of U.S. Patent No. 5,264,416.

[0025] As used herein, the term "TSLP polypeptide" refers to various forms of TSLP useful as immunogens. These include TSLP expressed in modified forms in which the furin cleavage site has been removed through modification of the amino acid sequence, as described in PCT Patent Application Publication WO03 / 032898. The modified TSLP retains activity, but the full-length sequence is more easily expressed in mammalian cells, such as CHO cells. Examples of TSLP polypeptides include SEQ ID NO:2, SEQ ID NO:373, and SEQ ID NO:375.

[0026] Additionally, a cynomolgus TSLP has been identified, which is shown in Example 1 below and is set forth, for example, in SEQ ID NO:380.

[0027] TSLP is produced in human epithelial cells, including skin, bronchial, tracheal, and airway epithelial cells, keratinocytes, interstitial and mast cells, smooth muscle cells, and lung and skin fibroblasts, as determined by quantitative mRNA analysis (Sou et al., 2013). Melis et al., Nature Immunol. 3(7)673-680 (2002). Both mouse and human TSLP have been implicated in promoting allergic inflammation.

[0028] [Table 1] TSLP activity TSLP activity includes proliferation of BAF cells expressing human TSLPR (BAF / HTR) as described in PCT Patent Application Publication WO03 / 032898. The BAF / HTR bioassay utilizes a mouse pro B lymphocyte cell line transfected with the human TSLP receptor. The BAF / HTR cells depend on huTSLP for growth and proliferate in response to active huTSLP added to the test sample. After an incubation period, cell proliferation is measured by adding Alamar Blue dye I or tritiated thymidine. Proliferation can also be measured using commercially available kits such as the CYQUANT Cell Proliferation Assay Kit (Invitrogen).

[0029] Additional assays for huTSLP activity include assays that measure the induction of T cell growth from human bone marrow by TSLP, as described, for example, in U.S. Patent No. 6,555,520. Another TSLP activity is the activity of activating STAT5, as described in Levin et al., J. Immunol. 162:677-683 (1999) and PCT patent application WO03 / 032898.

[0030] Further assays are described in U.S. Patent Application Publication No. 2006 / 0039910 (Serial No. 11 / 2 05,909) and includes TSLP-induced CCL17 / TARC production from primary human monocytic cells and dendritic cells.

[0031] Cell-based assays useful for measuring TSLP activity are described in the Examples below, including the BAF cell proliferation assay described above, and the primary cell assay described below that measures TSLP-induced osteoprotegerin (OPG) production from primary human dendritic cells, and the cynomolgus monkey peripheral blood mononuclear cell assay, also described below.

[0032] TSLP activity further includes in vivo activity. These can be measured in mouse models (e.g., as described in Zhou et al., Nat Immunol 6(10)1047-1053(2005) and Yoo et al., J Exp Med.202(4)541-549(2005)). For example, anti-mouse TSLP antibody has been shown to reduce BALF cellularity and BALF levels of IL-5 and Il-13 in the Ova-asthma model (Zhou et al.).

[0033] definition Polynucleotide and polypeptide sequences are shown using standard one-letter or three-letter abbreviations. Unless otherwise specified, a polypeptide sequence has its amino terminus on the left and its carboxy terminus on the right, and single-stranded nucleic acid sequences, and the top strand of double-stranded nucleic acid sequences, have their 5' terminus on the left and their 3' terminus on the right. A particular polypeptide or polynucleotide sequence may also be described by explaining how it differs from a reference sequence.

[0034] Polynucleotide and polypeptide sequences of particular light and heavy chain variable domains (L1 ("light chain variable domain 1"), H1 ("heavy chain variable domain 1"), etc.). Antibodies comprising light and heavy chains are designated by combining the name of the light chain variable domain and the name of the heavy chain variable domain. For example, "L4H7" designates an antibody comprising a light chain variable domain of L4 and a heavy chain variable domain of H7.

[0035] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by those skilled in the art. Furthermore, unless otherwise required by context, singular terms include pluralities and plural terms include the singular. In general, the technical terms and techniques related to cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the art. The methods and techniques of the present invention, unless otherwise specified, are generally carried out according to conventional methods well known in the art and described in various general and more specific references cited and discussed throughout this specification. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual See, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990), which are incorporated herein by reference. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are well known and understood to be of skill in the art. Standard techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients, as are commonly used in the art.

[0036] The following terms are understood to have the following meanings unless otherwise specified. The term "isolated molecule" (when the molecule is, for example, a polypeptide, polynucleotide, or antibody) refers to a molecule that, based on its origin or source of derivative, is (1) free from naturally associated components that accompany it in its natural state, (2) substantially free from other molecules from the same species, (3) expressed by cells from a different species, or (4) not naturally occurring. Thus, a molecule that is chemically synthesized or expressed in a cellular system different from the cell in which it naturally occurs is "isolated" from its naturally associated components. A molecule can also be rendered substantially free of naturally associated components by isolation, using purification techniques well known in the art. The purity or homogeneity of a molecule can be assayed by a number of methods well known in the art. For example, the purity of a polypeptide sample can be assayed using polyacrylamide gel electrophoresis and staining of the gel to visualize the polypeptide using techniques well known in the art. For certain purposes, higher resolution can be provided by using HPLC or other means well known in the art for purification.

[0037] The terms "TSLP inhibitor" and "TSLP antagonist" are used interchangeably. Each is a molecule that detectably inhibits TSLP signaling. The inhibition caused by a TSLP inhibitor does not have to be complete, as long as it is detectable using an assay. For example, the cell-based assay described in Example 4 below demonstrates a useful assay for measuring inhibition of TSLP signaling.

[0038] The terms "peptide," "polypeptide," and "protein" each refer to a molecule comprising two or more amino acid residues linked together by peptide bonds. These terms encompass, for example, natural and artificial proteins, protein fragments and polypeptide analogs of protein sequences (e.g., muteins, variants, and fusion proteins), as well as proteins that have been post-translationally or otherwise covalently or non-covalently modified. A peptide, polypeptide, or protein may be monomeric or polymeric.

[0039] As used herein, the term "polypeptide fragment" refers to a polypeptide that has an amino-terminal and / or carboxy-terminal deletion compared to the corresponding full-length protein. For example, a fragment can be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 50, 70, 80, 90, 100, 150, or 200 amino acids in length. For example, a fragment can also be at most 1,000, 750, 500, 250, 200, 175, 150, 125, 100, 90, 80, 70, 60, 50, 40, 30, 20, 15, 14, 13, 12, 11, or 10 amino acids in length. A fragment can further include one or more additional amino acids at either or both ends, such as a sequence of amino acids derived from a different naturally occurring protein (e.g., Fc or leucine zipper domain) or an artificial amino acid sequence (e.g., an artificial linker sequence).

[0040] Polypeptides of the invention include polypeptides that have been modified in any manner and for any reason, for example, to (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity to form protein complexes, (4) alter binding affinity, and (4) impart or modify other physicochemical or functional properties. Analogs include muteins of a polypeptide. For example, single or multiple amino acid substitutions (e.g., conservative amino acid substitutions) can be made in a naturally occurring sequence (e.g., in a portion of a polypeptide outside of the domains that form intermolecular contacts). A "conservative amino acid substitution" does not substantially change the structural features of the parent sequence (e.g., the substituted amino acid is a nucleotide that is not a nucleotide sequence that is present in the parent sequence). (It should not tend to disrupt the binding structure of the parent sequence or other types of secondary structure that characterize the parent sequence or are required for its functionality. Examples of art-recognized secondary and tertiary structures of polypeptides are described in Proteins, Structures and Molecular Principles (Creighton, ed., W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, NY (1991)); and Thornton et al., Nature 354:105 (1991), each of which is incorporated herein by reference.

[0041] A "variant" of a polypeptide includes an amino acid sequence in which one or more amino acid residues are inserted, deleted, and / or substituted from another polypeptide sequence. Variants of the invention include fusion proteins. Variants of the antibodies described herein also include those that result from processing. Such variants include those that have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more additional amino acids at the N-terminus of the light or heavy chain, for example, as a result of inefficient signal sequence cleavage. Such variants also include those that have one or more amino acids deleted from the N-terminus or C-terminus of the light or heavy chain.

[0042] A "derivative" of a polypeptide is a polypeptide (e.g., an antibody) that has been chemically modified, for example, through conjugation to another chemical moiety (e.g., polyethylene glycol, albumin (e.g., human serum albumin), etc.), phosphorylation, and glycosylation. Unless otherwise specified, the term "antibody" includes antibodies containing two full-length heavy chains and two full-length light chains, as well as derivatives, variants, fragments, and muteins thereof. Examples of these are described below.

[0043] An "antigen-binding protein" according to the present disclosure is a protein capable of binding to an antigen, and optionally a scaffold or framework moiety that allows the antigen-binding portion to adopt a conformation that facilitates binding of the antigen-binding protein to the antigen. In one embodiment, the antigen-binding protein of the present invention comprises at least one CDR. Examples of antigen-binding proteins include antibodies, antibody fragments (e.g., antigen-binding portions of antibodies), antibody derivatives, and antibody analogs. The antigen-binding protein may comprise, for example, alternative protein scaffolds or artificial scaffolds with grafted CDRs or CDR derivatives. Such scaffolds include, but are not limited to, antibody-derived scaffolds that contain introduced mutations that stabilize the three-dimensional structure of the antigen-binding protein, as well as fully synthetic scaffolds, including, for example, biocompatible polymers. See, e.g., Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, Vol. 53, No. 1: 121-129; Roque et al., 2004, Biotechnol. Prog. 20: 639-654. Additionally, peptide antibody mimetics ("PAMs") may be used, as well as scaffold-based antibody mimetics that utilize fibronectin components as the scaffold.

[0044] The antigen-binding protein may have, for example, the structure of a naturally occurring immunoglobulin. An "immunoglobulin" is a tetrameric molecule. In naturally occurring immunoglobulins, each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" chain (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain contains a variable region of about 100-110 or more amino acids that is responsible for antigen recognition. The carboxy-terminal portion of each chain defines a constant region that is responsible for effector action. Human Light chains are classified as kappa and lambda light chains. Heavy chains are classified as μ, δ, γ, α, or ε, which define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are linked by a "J" region of about 12 or more amino acids, with heavy chains also including a "D" region of about 10 more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989)), which is incorporated herein by reference in its entirety for all purposes. The variable regions of each light / heavy chain pair form the antibody binding site, such that an intact immunoglobulin has two binding sites.

[0045] Naturally occurring immunoglobulin chains exhibit a similar general structure of relatively conserved framework regions (FR) linked by three hypervariable regions (also called complementarity determining regions or CDRs). From the N-terminus to the C-terminus, both light and heavy chains contain the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is described in Kabat et al., Sequences of Proteins, 19 ... of Immunological Interest, 5th ed., US Dept. of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242, 1991. An intact antibody includes a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody, or a fully human antibody having full-length heavy and light chains.

[0046] "Antibody" refers to an intact immunoglobulin or antigen-binding portion thereof that competes with the intact antibody for specific binding, unless otherwise specified. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include Fab, Fab', F(ab')2, Fd, Fv, and domain antibodies (dAbs), as well as complementarity determining region (CDR) fragments, single chain antibodies (scFv), diabodies, triabodies, tetrabodies, and polypeptides that contain at least a portion of an immunoglobulin sufficient to confer specific antigen binding to the polypeptide.

[0047] The Fab fragment is V L , V H , C L and C H a F(ab')2 fragment is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment is a monovalent fragment having a V H Domain and C H an Fv fragment has one V domain; an Fv fragment has one V domain of a single arm of an antibody. L Domains and V H domain; and the dAb fragment has a V H Domain, V L Domain, or V H Or V L and antigen-binding fragments of the domain (U.S. Pat. Nos. 6,846,634, 6,696,245; U.S. Patent Application Publication Nos. 05 / 0202512, 04 / 0202995, 04 / 0038291, 04 / 0009507, 03 / 0039958; Ward et al., Nature 341:544-546, 1989).

[0048] Single chain antibodies (scFv) are L and V HDiabodies are antibodies in which the V domains are linked by a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous protein chain (wherein the linker is long enough to allow the protein chain to fold back on itself) and form a monovalent antigen-binding site (see, e.g., Bird et al., 1988, Science 242:423-26, and Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-83). Diabodies are bivalent antibodies comprising two polypeptide chains, where each polypeptide chain is linked by a V domain linked by a linker. H Domains and V L domains, the linker being too short to allow pairing between the two domains on the same chain, thus allowing each domain to pair with a complementary domain on another polypeptide chain (see, e.g., Holliger et al., (See, e.g., Proc. Natl. Acad. Sci. USA 90:6444-48, 1993, and Poljak et al., Structure 2:1121-23, 1994). When the two polypeptide chains of a diabody are identical, the diabody resulting from their pairing has two identical antigen-binding sites. Polypeptide chains with different sequences can be used to create diabodies with two different antigen-binding sites. Similarly, tribodies and tetrabodies are antibodies that contain three and four polypeptide chains, respectively, forming three and four antigen-binding sites, respectively, that may be identical or different.

[0049] The complementarity determining regions (CDRs) and framework regions (FRs) of a given antibody can be identified using the systematic method described by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, US Dept.of Health and Human Services, PHS, NIH, NIH Publication no. 91-3242, 1991. One or more CDRs can be incorporated into a molecule, either covalently or non-covalently, making the molecule an antigen-binding protein. An antigen-binding protein may incorporate the CDRs as part of a longer polypeptide chain, may covalently link the CDRs to another polypeptide chain, or may incorporate the CDRs non-covalently. These CDRs allow the antigen-binding protein to specifically bind to a particular antigen of interest.

[0050] An antigen-binding protein may have one or more binding sites. When there is more than one binding site, the binding sites may be identical or different from each other. For example, naturally occurring human immunoglobulins typically have two identical binding sites, while "bispecific" or "bifunctional" antibodies have two different binding sites.

[0051] The term "human antibody" includes all antibodies having one or more variable and constant regions derived from human immunoglobulin sequences. In one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies). These antibodies can be prepared in a variety of ways, examples of which are described below, including through immunization with the antigen of interest of mice that have been genetically modified to express antibodies derived from genes encoding human heavy and / or light chains.

[0052] A humanized antibody has a sequence that differs from that of an antibody obtained from a non-human species by the substitution, deletion and / or addition of one or more amino acids, such that the humanized antibody is less likely to provoke an immune response and / or provokes a less severe immune response when administered to a human subject compared to an antibody of the non-human species. In one embodiment, certain amino acids within the framework and constant domains of the heavy and / or light chains of an antibody of a non-human species are mutated to generate a humanized antibody. In another embodiment, a constant domain from a human antibody is fused to a variable domain of a non-human species. In another embodiment, one or more amino acid residues within one or more CDR sequences of a non-human antibody are altered to reduce the potential immunogenicity of the non-human antibody when administered to a human subject, where either the altered amino acid residue is not important for the immunospecific binding of the antibody to its antigen or the changes made to the amino acid sequence are conservative changes, such that the binding of the humanized antibody to the antigen is not significantly inferior to the binding of the non-human antibody to the antigen. Examples of methods for making humanized antibodies can be found in US Pat. Nos. 6,054,297, 5,886,152 and 5,877,293.

[0053] The term "chimeric antibody" refers to an antibody that contains one or more regions derived from one antibody and one or more regions derived from one or more other antibodies. In one embodiment, one or more of the CDRs are obtained from a human anti-TSLP antibody. In another embodiment, one or more of the CDRs are all of which are derived from a human anti-TSLP antibody. In another embodiment, CDRs from more than one human anti-TSLP antibody are mixed and matched within a chimeric antibody. For example, a chimeric antibody can contain CDR1 from the light chain of a first human anti-TSLP antibody, CDR2 and CDR3 from the light chain of a second human anti-TSLP antibody, and CDRs from the heavy chain of a third anti-TSLP antibody. Furthermore, the framework regions can be derived from one of the same anti-TSLP antibodies, one or more different antibodies (e.g., human antibodies), or humanized antibodies. In one example of a chimeric antibody, a portion of the heavy and / or light chains are identical to, homologous to, or derived from an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chains are identical to, homologous to, or derived from an antibody derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies that exhibit the desired biological activity (ie, the ability to specifically bind to the human TSLP receptor).

[0054] Antibody fragments or analogs can be easily prepared by those skilled in the art following the teachings of the present specification and using techniques well known in the art. The preferred amino and carboxy termini of the fragments or analogs are near the boundaries of the functional domains. Structural and functional domains can be identified by comparison of nucleotide and / or amino acid sequence data with public or proprietary sequence databases. Computerized comparison methods can be used to identify sequence motifs or predicted protein conformation domains present in other proteins with known structure and / or function. Methods for identifying protein sequences that fold into known three-dimensional structures are known. See, for example, Bowie et al., 1991, Science 253:164.

[0055] A "CDR-grafted antibody" is an antibody that comprises one or more CDRs derived from an antibody of a particular species or isotype and the framework of another antibody of the same or different species or isotype.

[0056] A "multispecific antibody" is an antibody that recognizes more than one epitope on one or more antigens. A subclass of this type of antibody is the "bispecific antibody," which recognizes two different epitopes on the same or different antigens.

[0057] Antigen-binding proteins, including antibodies, are -7 An antibody "specifically binds" to an antigen, such as TSLP, if it binds to that antigen with high binding affinity as determined by a Kd (or the corresponding Kb, defined below) value of less than or equal to M.

[0058] An "antigen-binding domain," "antigen-binding region," or "antigen-binding site" is a part of an antigen-binding protein that contains the amino acid residues (or other moieties) that interact with an antigen and contribute to the specificity and affinity of the antigen-binding protein for its antigen. For an antibody that specifically binds to an antigen, this includes at least a portion of at least one of its CDR domains.

[0059] The "percent identity" of two polynucleotide sequences or two polypeptide sequences is determined by comparing the sequences using the GAP computer program (part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters.

[0060] The terms "polynucleotide," "oligonucleotide," and "nucleic acid" are used interchangeably throughout and refer to DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), DNA or RNA molecules produced using nucleotide analogs (e.g., peptide nucleic acids and non-naturally occurring nucleotide analogs). The nucleic acid molecule may be single-stranded or double-stranded. In one embodiment, the nucleic acid molecule of the invention comprises a contiguous open reading frame encoding an antibody of the invention, or a fragment, derivative, mutein, or variant thereof.

[0061] Two single-stranded polynucleotides are "complementary" to each other if their sequences can be aligned in antiparallel orientation, so that every nucleotide in one polynucleotide faces its complementary nucleotide in the other polynucleotide without introducing gaps and without unpaired nucleotides at the 5' or 3' end of either sequence. Two polynucleotides are "complementary" to another polynucleotide if they can hybridize to each other under moderately stringent conditions. Thus, a polynucleotide can be complementary to another polynucleotide that is not its complementary strand.

[0062] A "vector" is a nucleic acid that can be used to introduce another nucleic acid linked to it into a cell. One type of vector is a "plasmid", which refers to a linear or circular double-stranded DNA molecule to which additional nucleic acid segments can be ligated. Another type of vector is a viral vector (e.g., replication-defective retroviruses, adenoviruses and adeno-associated viruses), in which additional DNA segments can be introduced into the viral genome. Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors containing a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and are thereby replicated together with the host genome. An "expression vector" is a type of vector that can induce the expression of a selected polynucleotide.

[0063] A nucleotide sequence is "operably linked" to a regulatory sequence if the regulatory sequence affects the expression (e.g., level, timing, or location of expression) of the nucleotide sequence. A "regulatory sequence" is a nucleic acid that affects the expression (e.g., level, timing, or location of expression) of a nucleic acid to which it is operably linked. A regulatory sequence may, for example, exert its effect on the regulated nucleic acid directly or through the action of one or more other molecules (e.g., a polypeptide that binds to the regulatory sequence and / or the nucleic acid). Examples of regulatory sequences include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Further examples of regulatory sequences are described, for example, in Goeddel, 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA, and Baron et al., 1995, Nucleic Acids Res. 23:3605-06.

[0064] A "host cell" is a cell that can be used to express a nucleic acid (e.g., a nucleic acid of the invention). A host cell can be a prokaryote (e.g., E. coli), or it can be a eukaryote, such as a unicellular eukaryote (e.g., a yeast or other fungus), a plant cell (e.g., a tobacco or tomato plant cell), an animal cell (e.g., a human cell, a monkey cell, a hamster cell, a rat cell, a mouse cell, or an insect cell), or a hybridoma. Exemplary host cells include Chinese hamster ovary (CHO) cell lines or derivatives thereof, including the CHO line DXB-11, which is deficient in DHFR (see Urlaub et al., 1980, Proc. Natl. Acad. Sci. USA 77:4216-20), CHO cell lines that grow in serum-free medium (see Rasmussen et al., 1998, Cytotechnology 28:31), CS-9 cells (a derivative of DXB-11 CHO cells) and AM-1 / D cells (described in U.S. Pat. No. 6,210,924). Other CHO cell lines include CHO-K1 (ATCC# CCL-61), EM9 (ATCC# CRL-1861) and UV20 (ATCC# CRL-1862). Examples of other host cells include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (see Gluzman et al., 1981, Cell 23:175), L cells, C127 cells, 3T3 cells (ATCC CCL 163), HeLa cells, BHK (ATCC CRL 10) cell lines, the CV1 / EBNA cell line (ATCC CCL 70) derived from the African green monkey kidney cell line CV1 (see McMahan et al., 1991, EMBO J. 10:2821), human embryonic kidney cells such as 293, 293 EBNA or MSR 293, human epithelial A431 cells, human Colo205 cells, other transformed primate cell lines, normal diploid cells, cell lines derived from in vitro culture of primary tissue, primary explants, HL-60, U937, HaK or Jurkat cells. Typically, a host cell is a cultured cell that can be transformed or transfected with a nucleic acid encoding a polypeptide, which can then be expressed in the host cell. The phrase "recombinant host cell" can be used to mean a host cell that has been transformed or transfected with a nucleic acid to be expressed. A host cell can also be a cell that contains a nucleic acid but does not express the nucleic acid at a desired level unless a regulatory sequence is introduced into the host cell so that it is operably linked to the nucleic acid. It is understood that the term host cell refers not only to the particular subject cell, but also to the progeny or potential progeny of such a cell. In fact, such progeny may not be identical to the parent cell, since certain modifications may occur in successive generations, for example due to mutation or environmental influences, but still fall within the scope of the term as used herein.

[0065] Antigen-binding proteins In one aspect, the present disclosure provides antigen-binding proteins, such as antibodies, antibody fragments, antibody derivatives, antibody muteins, and antibody variants, that bind to human TSLP. Antigen-binding proteins according to the present disclosure include antigen-binding proteins that bind to human TSLP, thereby reducing TSLP activity. For example, antigen-binding proteins can interfere with the binding of TSLP to its receptor, thus reducing TSLP activity.

[0066] In one embodiment, the invention provides an antigen binding protein comprising one or more CDR sequences which differ from the CDR sequences shown in Figures 1A-1F or Figures 2A-2F by no more than 5, no more than 4, no more than 3, no more than 2, no more than 1 or no more than 0 amino acid residues.

[0067] In another embodiment, at least one of the CDR3 sequences of the antigen binding protein is a sequence of Figures 1A-1F or 2A-2F. In another embodiment, the light chain CDR3 sequence of the antigen binding protein is a light chain sequence of A1-A27 and the heavy chain CDR3 sequence of the antigen binding protein is a heavy chain CDR3 sequence of A1-A27.

[0068] In another embodiment, the antigen binding protein further comprises one, two, three, four or five CDR sequences, each of which independently differs from the CDR sequences of A1-A27 by 5, 4, 3, 2, 1 or 0 single amino acid additions, substitutions and / or deletions. The sequences of the light chain CDRs of exemplary antigen binding proteins A1-A27 and the sequences of the heavy chain CDRs of exemplary binding proteins A1-A27 are shown in Figures 1A-1F and 2A-2F, respectively. Polynucleotide sequences encoding the amino acid sequences of the CDRs are also shown. Additionally, consensus sequences for the CDR sequences are provided below.

[0069]

number

[0070]

number

[0071]

number

[0072]

number

[0073]

number

[0074] Table 2 below provides the nucleic acid (DNA) sequences encoding the variable heavy domain (H#) and variable light domain (L#), and the amino acid sequences of the variable heavy and light domains, respectively, for exemplary TSLP antigen binding proteins A1-A27. CDRs 1, 2, and 3 for each variable domain are contiguous from beginning to end of each sequence. Framework (Fr) regions are underlined. Frameworks 1, 2, 3, and 4 for each variable domain are contiguous from beginning to end of each sequence. (For example, in each sequence, the first underlined portion of the sequence is Fr1, the second is Fr2, the third is Fr3, and the last is Fr4).

[0075] [Table 2-1]

[0076] [Table 2-2]

[0077] [Table 2-3]

[0078]

Table 2-4

[0079]

Table 2-5

[0080]

Table 2-6

[0081]

Table 2-7

[0082]

Table 2-8

[0083]

Table 2-9

[0084]

Table 2-10

[0085]

Table 2-11

[0086]

Table 2-12

[0087]

Table 2-13

[0088] [Table 2-14]

[0089] [Table 2-15]

[0090] [Table 2-16] Certain embodiments of the antigen binding proteins of the present invention comprise one or more amino acid sequences identical to the amino acid sequences of one or more of the CDRs and may further comprise one or more FRs as shown above. In one embodiment, the antigen binding protein comprises a light chain CDR1 sequence as shown above. In another embodiment, the antigen binding protein comprises a light chain CDR2 sequence as shown above. In another embodiment, the antigen binding protein comprises a light chain CDR3 sequence as shown above. In another embodiment, the antigen binding protein comprises a heavy chain CDR1 sequence as shown above. In another embodiment, the antigen binding protein comprises a heavy chain CDR2 sequence as shown above. In another embodiment, the antigen binding protein comprises a heavy chain CDR3 sequence as shown above. In another embodiment, the antigen binding protein further comprises a light chain CDR3 sequence as shown above. In addition, the antigen binding protein comprises a light chain FR1 sequence as shown above. In another embodiment, the antigen binding protein further comprises a light chain FR2 sequence as shown above. In another embodiment, the antigen binding protein further comprises a light chain FR3 sequence as shown above. In another embodiment, the antigen binding protein further comprises a light chain FR4 sequence as shown above. In another embodiment, the antigen binding protein further comprises a heavy chain FR1 sequence as shown above. In another embodiment, the antigen binding protein further comprises a heavy chain FR2 sequence as shown above. In another embodiment, the antigen binding protein further comprises a heavy chain FR3 sequence as shown above. In another embodiment, the antigen binding protein further comprises a heavy chain FR4 sequence as shown above.

[0091] In one embodiment, the disclosure provides an antigen binding protein comprising a light chain variable domain comprising a sequence of amino acids that differs by only 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 residues from a sequence of a light chain variable domain selected from the group consisting of L1-L27, wherein each such sequence difference is independently either a deletion, insertion or substitution of one amino acid residue. In another embodiment, the light chain variable domain comprises a sequence of amino acids that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% identical to a sequence of a light chain variable domain selected from the group consisting of L1-L27. In another embodiment, the light chain variable domain comprises a sequence of amino acids encoded by a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% identical to a nucleotide sequence encoding a light chain variable domain selected from the group consisting of L1 to L27. In another embodiment, the light chain variable domain comprises a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to a complementary strand of a polynucleotide encoding a light chain variable domain selected from the group consisting of L1 to L27. In another embodiment, the light chain variable domain comprises a sequence of amino acids encoded by a polynucleotide that hybridizes under highly stringent conditions to a complementary strand of a light chain polynucleotide of L1 to L27.

[0092] In another embodiment, the invention provides an antigen binding protein comprising a heavy chain variable domain comprising a sequence of amino acids that differs by only 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 residues from a sequence of a heavy chain variable domain selected from the group consisting of H1 to H27, wherein each such sequence difference is independently either a deletion, insertion or substitution of one amino acid residue. In another embodiment, the heavy chain variable domain comprises a sequence of amino acids that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% identical to a sequence of a heavy chain variable domain selected from the group consisting of H1 to H27. In another embodiment, the heavy chain variable domain comprises a sequence of amino acids encoded by a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 97% or 99% identical to a nucleotide sequence encoding a heavy chain variable domain selected from the group consisting of H1 to H27. In another embodiment, the heavy chain variable domain comprises a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to a complementary strand of a polynucleotide encoding a heavy chain variable domain selected from the group consisting of H1 to H27. In another embodiment, the heavy chain variable domain comprises a sequence of amino acids encoded by a polynucleotide that hybridizes under highly stringent conditions to a complementary strand of a polynucleotide encoding a heavy chain variable domain selected from the group consisting of H1 to H27.

[0093] In some of the embodiments provided in Table 2 above, two light chains are combined with a single heavy chain, identified as, for example, L-12.1, L-12.2, etc. These alternative light chains each pair with a single heavy chain. In these embodiments, the combination of light and heavy chains The combinations can be assayed as described below, and the light and heavy chain combination that provides the greater TSLP-neutralizing activity can be selected.

[0094] Further embodiments include antigen binding proteins comprising the combinations L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26 and L27H27.

[0095] The antigen-binding proteins (e.g., antibodies, antibody fragments and antibody derivatives) of the present invention may further comprise any constant region known in the art. The light chain constant region may be, for example, a kappa- or lambda-type light chain constant region (e.g., a human kappa- or lambda-type light chain constant region). The heavy chain constant region may be, for example, an alpha-, delta-, epsilon-, gamma- or mu-type heavy chain constant region (e.g., a human alpha-, delta-, epsilon-, gamma- or mu-type heavy chain constant region). In one embodiment, the light or heavy chain constant region is a fragment, derivative, variant or mutein of a naturally occurring constant region.

[0096] In one embodiment, the antigen binding protein comprises an IgG, such as IgG1, IgG2, IgG3 or IgG4.

[0097] Techniques for obtaining antibodies of a different subclass or isotype from an antibody of interest (i.e., subclass switching) are known. Thus, for example, an IgG antibody can be obtained from an IgM antibody, and vice versa. Such techniques allow the preparation of novel antibodies that have the antigen-binding properties of a given antibody (parent antibody), but also exhibit biological properties associated with an antibody isotype or subclass different from that of the parent antibody. Recombinant DNA techniques can be used. Cloned DNA encoding a particular antibody polypeptide (e.g., DNA encoding the constant domain of an antibody of a desired isotype) can be used in such procedures. See also Lantto et al., 2002, Methods Mol. Biol. 178:303-16.

[0098] In one embodiment, the antigen binding protein of the invention comprises an IgG1 heavy chain constant domain or a fragment of an IgG1 heavy chain domain. In one embodiment, the antigen binding protein of the invention further comprises a light chain kappa constant domain or a light chain lambda constant domain or a fragment thereof. Light chain constant regions, and the polynucleotides encoding them, are provided in Table 3 below. In another embodiment, the antigen binding protein of the invention further comprises a heavy chain constant domain, such as the IgG2 heavy chain constant regions shown in Table 3 below, or a fragment thereof.

[0099] Nucleic acids (DNA) encoding heavy and light chain constant domains, as well as the amino acid sequences of the heavy and light chain domains, are provided below. A λ variable domain can be fused to a λ constant domain, and a K variable domain can be fused to a K constant domain.

[0100] [Table 3] Antigen binding proteins of the invention include, for example, variable domain combinations L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13.1H13, L13.2H13, L14.1H14, L14. 2H14, L15.1H15, L15.2H15, L16.1H16, L16.2H16, L17H17, L18.1H18, L18.2H18, L19.1H19, L19.2H19, L20.1H20, L20.2H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26 and L27H27, as well as Fab or F(ab')2 fragments thereof. Furthermore, if IgG4 is desired, it may be desirable to introduce point mutations in the hinge region to reduce the tendency to form intra-H chain disulfide bonds that can lead to heterogeneity of IgG4 antibodies, as described in Bloom et al., 1997, Protein Science 6:407 (incorporated herein by reference).

[0101] Antibodies and antibody fragments As used herein, the term "antibody" refers to an intact antibody or an antigen-binding fragment thereof, as described in the definition section herein. Antibodies may include complete antibody molecules (including polyclonal, monoclonal, chimeric, humanized or human versions with full-length heavy and / or light chains) or may include antigen-binding fragments thereof. Antibody fragments include F(ab')2 fragments, Fab fragments, Fab' fragments, Fv fragments, Fc fragments and Fd fragments, which may be incorporated into single domain antibodies, monovalent antibodies, single chain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFvs (see, e.g., Hollinger and Hudson, 2005, Nature Biotechnology, 23, 9, 1126-1136). Antibody polypeptides, including fibronectin polypeptide monobodies, are also disclosed in U.S. Patent No. 6,703,199. Other antibody polypeptides are disclosed in U.S. Patent Application Publication No. 2005 / 0238646, which are single chain polypeptides. Monovalent antibody fragments are disclosed in U.S. Patent Application Publication No. 20050227324.

[0102] Antigen-binding fragments derived from antibodies can be obtained, for example, by proteolytic hydrolysis of antibodies (e.g., pepsin or papain digestion of whole antibodies according to conventional methods). By way of example, antibody fragments can be produced by enzymatic cleavage of antibodies using pepsin to provide a 5S fragment designated F(ab')2. This fragment can be further cleaved using a thiol reducing agent to yield a 3.5S Fab' monovalent fragment. Optionally, the cleavage reaction can be carried out using a blocking group for the sulfhydryl groups resulting from cleavage of disulfide bonds. As an alternative, enzymatic cleavage using papain directly yields two monovalent Fab fragments and one Fc fragment. These methods are described, for example, in Goldenberg, U.S. Pat. No. 4,331,647; Nisonoff et al., Arch. Biochem. Biophys. 89:230, 1960; Porter, Biochem. J. 73:119, 1959; Edelman et al., Methods in Enzymology 1:422 (Academic Press 1967); and by Andrews, SM and Titus, JA, Current Protocols in Immunology (Coligan JE et al., eds.), John Wiley & Sons, New York (2003), pp. 2.8.1-2.8.10 and 2.10A.1-2.10A.5. Other methods for cleaving antibodies, such as separating the heavy chains to form monovalent light-heavy chain fragments (Fd), further cleavage of the fragments, or other enzymatic, chemical or genetic techniques, can also be used so long as the fragment binds to the antigen recognized by the intact antibody.

[0103] An antibody fragment may also be any synthetic or genetically engineered protein. For example, an antibody fragment may include an isolated fragment consisting of a light chain variable region, an "Fv" fragment consisting of the variable regions of a heavy and light chain, or a recombinant single chain polypeptide molecule in which the light and heavy chain variable regions are connected by a peptide linker (scFv protein).

[0104] Another form of antibody fragment is a peptide containing one or more complementarity determining regions (CDRs) of an antibody. CDRs (also called "minimal recognition units" or "hypervariable regions") can be obtained by constructing polynucleotides encoding the CDRs of interest. Such polynucleotides are prepared, for example, by using the polymerase chain reaction to synthesize the variable regions using mRNA from antibody-producing cells as a template (see, for example, Larrick et al., Methods: A Companion to Methods in Enzymes). ology 2:106, 1991;Courtenay-Luck, “Genetic (eds.), p. 166 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," Monoclonal Antibodies: Principles and Applications, Birch et al. (eds.), p. 137 (Wiley-Liss, Inc. 1995).

[0105] Thus, in one embodiment, the binding agent comprises at least one CDR as described herein. The binding agent may comprise at least two, three, four, five or six CDRs as described herein. The binding agent may further comprise at least one variable region domain of an antibody as described herein. The variable region domain may be of any size or amino acid composition and generally comprises at least one CDR sequence involved in binding to TSLP (e.g., heavy chain CDR1, CDR2, CDR3 and / or light chain CDRs as specifically described herein), which CDR sequence is adjacent to or in frame with one or more framework sequences. Generally, the variable (V) region domain comprises an immunoglobulin heavy (V H ) chain variable domain and / or light (V L ) chain variable domains. Thus, for example, the V region domains can be monomeric and contain at least 1×10 -7 V that can bind human TSLP independently with an affinity equal to or less than M H or V L Alternatively, the V region domain may be a dimer and may be a V H -V H , V H -V L or V L -V L The V region dimer may comprise at least one V domain that can be non-covalently associated. H A chain and at least one V L chain (hereafter, F V If desired, the chains can be covalently coupled either directly through a disulfide bond between the two variable domains or via a linker (e.g., a peptide linker) to form a single-chain Fv (scF V ) can be formed.

[0106] Said variable region domain can be any naturally occurring variable domain or its engineered version.By engineered version, it is meant the variable region domain made using recombinant DNA engineering technology.Such engineered versions include, for example, those made from the variable region of a specific antibody by inserting, deleting or changing in or to the amino acid sequence of the specific antibody.A specific example includes an engineered variable region domain that comprises at least one CDR and optionally one or more framework amino acids from a first antibody and the remainder of the variable region domain from a second antibody.

[0107] The variable region domains described above can be covalently attached at the C-terminal amino acid to at least one other antibody domain or fragment thereof. Thus, for example, a VH domain present in the variable region domain can be linked to an immunoglobulin CH1 domain or fragment thereof. Similarly, a V L The domain is C K In this way, for example, an antibody can be constructed such that its antigen-binding domain is linked to a bound V H Domains and V L Domain (this V H Domains and V L The domains are CH1 and C at their C-termini, respectively. K The CH1 domain may be a Fab fragment containing a CH1 domain covalently linked to the CH1 domain. The CH1 domain may be extended with additional amino acids, for example to provide a hinge region or part of a hinge region domain found in a Fab' fragment, or to provide additional domains such as antibody CH2 and CH3 domains.

[0108] Derivatives of antigen-binding proteins The nucleotide sequences shown in Figures 1A-1F, 2A-2F, and Table 2 above can be modified, for example, by random mutagenesis or site-directed mutagenesis (e.g., oligonucleotide-guided site-specific mutagenesis) to generate modified polynucleotides that contain one or more specific nucleotide substitutions, deletions, or insertions compared to the unmutated polynucleotide. Examples of techniques for generating such modifications are described in Walder et al., 1986, Gene 42:133; Bauer et al., 1985, Gene 37:73; Craik, BioTechniques, January 1985, 12-19; ​​Smith et al., 1981, Genetic Engineering: Principles and Methods, Plenum Press; and U.S. Patent Nos. 4,518,584 and 4,737,462. These and other methods can be used, for example, to generate derivatives of TSLP antigen-binding proteins that have desired properties (e.g., increased affinity, avidity or specificity for TSLP, increased activity or stability in vivo or in vitro, or reduced in vivo side effects, compared to the underivatized antigen-binding protein).

[0109] Other derivatives of anti-TSLP antigen-binding proteins, including antibodies, within the scope of the present invention include covalent or aggregate conjugates of anti-TSLP antibodies or fragments thereof with other proteins or polypeptides, such as by expression of recombinant fusion proteins containing heterologous polypeptides fused to the N-terminus or C-terminus of the anti-TSLP antibody polypeptide. For example, the conjugated peptide can be a heterologous signal (or leader) polypeptide (e.g., yeast α-factor leader) or a peptide such as an epitope tag. The antigen-binding protein-containing fusion protein can include a peptide (e.g., poly-His) added to facilitate purification or identification of the antigen-binding protein. The antigen-binding protein can also be linked to a FLAG peptide as described in Hopp et al., Bio / Technology 6:1204, 1988 and U.S. Patent No. 5,011,912. The FLAG peptide is highly antigenic and provides an epitope that is reversibly bound by a specific monoclonal antibody (mAb), allowing for rapid assay and easy purification of the expressed recombinant protein. Reagents useful for preparing fusion proteins in which the FLAG peptide is fused to a given polypeptide are commercially available (Sigma, St. Louis, Mo.).

[0110] Oligomers comprising one or more antigen-binding proteins can be used as TSLP antagonists.Oligomers can be in the form of covalently or non-covalently linked dimers, trimers or higher oligomers.Oligomers comprising two or more antigen-binding proteins are contemplated for use, one example of which is homodimers.Other oligomers include heterodimers, homotrimers, heterotrimers, homotetramers, heterotetramers, etc.

[0111] One embodiment relates to oligomers comprising multiple antigen binding proteins linked via covalent or non-covalent interactions between peptide moieties fused to the antigen binding proteins. Such peptides can be peptide linkers (spacers) or peptides with properties that promote oligomerization. Leucine zippers and certain polypeptides derived from antibodies are among the peptides that can promote oligomerization of antigen binding proteins attached to the peptides, as described in more detail below.

[0112] In certain embodiments, the oligomer comprises two to four antigen binding proteins capable of binding to TSLP. The antigen binding proteins of the oligomer can be in any form, such as any of the forms described above (e.g., variants or fragments).

[0113] In one embodiment, oligomers are prepared using polypeptides derived from immunoglobulins. Preparation of fusion proteins containing specific heterologous polypeptides fused to various portions of antibody-derived polypeptides (including Fc domains) is described, for example, by Ashkenazi et al., 1991, PNAS USA 88:10535; Byrn et al., 1990, Nature 344:677; and Hollenbaugh et al., 1992 "Construction of Immunoglobulin Fusion Proteins", Current Protocols in Immunology, Supplement 4, pages 10.19.1 to 10.19.11.

[0114] One embodiment of the present invention relates to a dimer comprising two fusion proteins made by fusing fragments of an anti-TSLP antibody to the Fc region of an antibody, which can be made, for example, by inserting a gene fusion encoding the fusion protein into an appropriate expression vector, expressing the gene fusion in a host cell transformed with the recombinant expression vector, and allowing the expressed fusion proteins to assemble in a manner that mimics an antibody molecule, where interchain disulfide bonds form between the Fc portions to obtain a dimer.

[0115] As used herein, the term "Fc polypeptide" includes native and mutein forms of polypeptides derived from the Fc region of an antibody. Also included are truncated forms of such polypeptides that contain the hinge region that promotes dimerization. Fusion proteins (and oligomers formed therefrom) that contain Fc portions offer the advantage of easy purification by affinity chromatography over protein A or protein G columns.

[0116] One suitable Fc polypeptide, described in PCT Patent Application WO93 / 10151 (herein incorporated by reference), is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is the Fc mutein described in U.S. Patent No. 5,457,035 and Baum et al., 1994, EMBO J. 13:3992-4001. The amino acid sequence of this mutein is identical to that of the native Fc sequence presented in WO93 / 10151, except that amino acid 19 is changed from Leu to Ala, amino acid 20 is changed from Leu to Glu, and amino acid 22 is changed from Gly to Ala. This mutein exhibits reduced affinity for Fc receptors.

[0117] In other embodiments, the variable portions of the heavy and / or light chains of an anti-TSLP antibody can be substituted for the variable portions of the antibody heavy and / or light chains.

[0118] Alternatively, the oligomer is a fusion protein comprising multiple antigen-binding proteins, with or without a peptide linker (spacer peptide). Among the suitable peptide linkers are those described in U.S. Patent Nos. 4,751,180 and 4,935,233.

[0119] Another method for preparing oligomeric antigen-binding proteins involves the use of leucine zippers. Leucine zipper domains are peptides that promote oligomerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., 1988, Science 240:1759) and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and their derivatives that dimerize or trimerize. Examples of leucine zipper domains suitable for generating soluble oligomeric proteins are described in PCT Patent Application No. WO 94 / 10308, and the leucine zipper derived from pulmonary surfactant protein D (SPD) is described in Hoppe et al., 1994, FEBS Letters 344:191, which is incorporated herein by reference. The use of modified leucine zippers that allow for stable trimerization of heterologous proteins fused thereto is described in Fanslow et al., 1994, Semin. Immunol. 6:267-78. In one approach, recombinant fusion proteins containing an anti-TSLP antibody fragment or derivative fused to a leucine zipper peptide are expressed in suitable host cells and the soluble oligomeric anti-TSLP antibody fragment or derivative that forms is recovered from the culture supernatant.

[0120] As described herein, an antibody comprises at least one CDR. For example, one or more CDRs can be incorporated into known antibody framework regions (such as IgG1, IgG2, etc.) or conjugated to a suitable vehicle that increases its half-life. Suitable vehicles include, but are not limited to, Fc, polyethylene glycol (PEG), albumin, and transferrin. These and other suitable vehicles are known in the art. Such conjugated CDR peptides can be in monomeric, dimeric, tetrameric, or other forms. In one embodiment, one or more water-soluble polymers are conjugated to one or more specific positions (e.g., amino termini) of the binding agent.

[0121] In certain preferred embodiments, the antibody comprises one or more water-soluble polymer attachments, including but not limited to polyethylene glycol, polyoxyethylene glycol or polypropylene glycol. See, for example, U.S. Patent Nos. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 and 4,179,337. In certain embodiments, the derivative binding agent comprises one or more monomethoxy-polyethylene glycol, dextran, cellulose or other carbohydrate-based polymers, poly(N-vinylpyrrolidone)-polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyol (e.g., glycerol) and polyvinyl alcohol, and mixtures of such polymers. In certain embodiments, one or more water-soluble polymers are randomly attached to one or more side chains. In certain embodiments, PEG can act to improve the therapeutic capacity of a binding agent (e.g., an antibody). Certain such methods are discussed, for example, in U.S. Patent No. 6,133,426, which is incorporated herein by reference for any purpose.

[0122] It is recognized that the antibody of the present invention may contain at least one amino acid substitution, deletion or addition, provided that the antibody retains binding specificity. Thus, modifications to the antibody structure are included within the scope of the present invention. These may include amino acid substitutions, which may be conservative or non-conservative, that do not destroy the antibody's ability to bind human TSLP. Conservative amino acid substitutions may include non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in a biological system. These include peptidomimetics and other reversed or inverted forms of amino acid moieties. Conservative amino acid substitutions may also include the replacement of natural amino acid residues with standard residues, resulting in little or no effect on the polarity or charge of the amino acid residue at that position.

[0123] Non-conservative substitutions may involve exchanging a member of one class of amino acid or amino acid mimetic for a member from another class having different physical properties (e.g., size, polarity, hydrophobicity, charge). Such substituted residues may be introduced into regions of the human antibody that are homologous with the non-human antibody, or may be introduced into the non-homologous regions of the molecule.

[0124] Moreover, one skilled in the art can generate test variants that contain single amino acid substitutions at each desired amino acid residue. These variants can then be screened using activity assays known to those skilled in the art. Such variants can be used to gather information about suitable variants. For example, when it is found that a change to a particular amino acid residue destroys, reduces undesirably, or causes inappropriate activity, the variant with such a change can be avoided. In other words, based on the information gathered from such routine experiments, one skilled in the art can easily determine the amino acids for which further substitutions should be avoided, either alone or in combination with other mutations.

[0125] Those skilled in the art can use well-known techniques to determine suitable variants of the polypeptides shown herein.In certain embodiments, those skilled in the art can identify suitable regions of the molecule that can be modified without destroying activity by targeting regions that are not considered important for activity.In certain embodiments, those residues and parts of the molecule that are conserved between similar polypeptides can be identified.In certain embodiments, even regions that may be important for biological activity or structure can be subjected to conservative amino acid substitutions without destroying biological activity and without adversely affecting polypeptide structure.

[0126] Moreover, one skilled in the art can review structure-function studies that have identified residues in similar polypeptides that are important for activity or structure. In light of such comparisons, one can predict the importance of amino acid residues in a protein that correspond to amino acid residues that are important for activity or structure in similar proteins. One skilled in the art can select amino acid substitutions that are chemically similar to such predicted important amino acid residues.

[0127] One skilled in the art may also analyze the three-dimensional structure and amino acid sequence in relation to its structure in similar polypeptides. In view of such information, one skilled in the art may predict the alignment of the amino acid residues of an antibody with respect to its three-dimensional structure. In certain embodiments, one skilled in the art may choose not to make drastic changes to amino acid residues predicted to be on the surface of the protein, because such residues may be involved in important interactions with other molecules.

[0128] Many scientific publications have been devoted to the prediction of secondary structure. See Moult J., Curr. Op. in Biotech., 7(4):422-427 (1996); Chou et al., Biochemistry, 13(2):222-245 (1974); Chou et al., Biochemistry, 113(2):211-222 (1974); Chou et al., Adv. Enzymol. Relat. Areas Mol. Biol., 47:45-148 (1978); Chou et al., Ann. Rev. Biochem., 47:251-276 and Chou et al., Biophys. J., 26:367-384 (1979). In addition, computer programs are now available to aid in the prediction of secondary structure. One method of predicting secondary structure is based on homology modeling. For example, two polypeptides or proteins with more than 30% sequence identity or more than 40% similarity often have similar structural topologies. The recent growth of the protein structural database (PDB) has provided increased predictability of secondary structure, including the possible number of folds within a polypeptide's or protein's structure. See Holm et al., Nucl. Acid. Res., 27(1):244-247 (1999). It has been suggested that there are a limited number of folds within a given polypeptide or protein, and that once a critical number of structures have been solved, structure prediction becomes dramatically more accelerated (Brenner et al., Curr. Op. Struct. Biol., 7(3):369-376 (1997)).

[0129] Additional methods for predicting secondary structure include "threading" (Jones, D., Curr. Opin. Struct. Biol., 7(3):377-87 (1997); Sippl et al., Structure, 4(1):15-19 (1996)), "profile analysis" (Bowie et al., Science, 253:164-170 (1991); Gribskov et al., Meth. Enzym., 183:146-159 (1990); Gribskov et al., Proc. Nat. Acad. Sci., 84(13):4355-4358 (1987)), and "evolutionary linkage" (see Holm, supra (1999) and Brenner, supra (1997)).

[0130] Those skilled in the art understand that some proteins (e.g., antibodies) can undergo various post-translational modifications. The type and extent of these modifications often depend on the host cell line and culture conditions used to express the protein. Such modifications include variations in glycosylation, oxidation of methionine, diketopiperidine formation, aspartic acid isomerization and asparagine amide degradation. A frequent modification is the loss of basic residues (e.g., lysine or arginine) at the carboxy terminus due to the action of carboxypeptidase (described in Harris, RJ, Journal of Chromatography 705:129-134, 1995).

[0131] In certain embodiments, antibody variants include glycosylation variants in which the number and / or type of glycosylation sites are altered compared to the amino acid sequence of the parent polypeptide. In certain embodiments, the variants contain more or fewer N-linked glycosylation sites than the native protein. Alternatively, substitutions that eliminate this sequence remove existing N-linked carbohydrate chains. Rearrangements of N-linked carbohydrate chains are also provided in which one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Further preferred antibody variants include cysteine ​​variants in which one or more cysteine ​​residues are deleted or replaced with another amino acid (e.g., serine) compared to the parent amino acid sequence. Cysteine ​​variants may be useful, for example, when an antibody must be refolded into a biologically active conformation after isolation of insoluble inclusion bodies. Generally, cysteine ​​variants have fewer cysteine ​​residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

[0132] Desired amino acid substitutions (whether conservative or non-conservative) can be determined by one of skill in the art at the time such substitutions are desired. In certain embodiments, amino acid substitutions can be used to identify key residues of antibodies to human TSLP or to increase or decrease the affinity of the antibodies to human TSLP described herein.

[0133] According to certain embodiments, preferred amino acid substitutions are those that (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity to form protein complexes, (4) alter binding affinity, and / or (4) confer or modify other physicochemical or functional properties to such polypeptides. According to certain embodiments, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) may be made in the naturally occurring sequence (in certain embodiments, in the portion of the polypeptide outside the domain that forms intermolecular contacts). In certain embodiments, conservative amino acid substitutions typically may not substantially alter the structural features of the parent sequence (e.g., the substituted amino acid should not tend to disrupt helices present in the parent sequence or other types of secondary structure that characterize the parent sequence). Examples of art-recognized secondary and tertiary structures of polypeptides are described in Proteins, Structures and Molecular Principles (ed. Creighton, W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (eds. C. Branden and J. Tooze, Garland Publishing, New York, NY (1991)); and Thornton et al., Nature 354:105 (1991), each of which is incorporated herein by reference.

[0134] In certain embodiments, the antibodies of the present invention may be chemically coupled to polymers, lipids, or other moieties.

[0135] Furthermore, the antigen-binding protein may comprise at least one of the CDRs described herein incorporated into a biocompatible framework structure. In one example, the biocompatible framework structure comprises a polypeptide or a portion thereof sufficient to form a conformationally stable structural support or framework or scaffold, which may present, in a localized surface region, one or more sequences of amino acids (e.g., CDRs, variable regions, etc.) that bind to the antigen. Such structures may be naturally occurring polypeptides or "folds" of polypeptides (structural motifs) or may have one or more modifications, such as additions, deletions, or substitutions of amino acids, compared to naturally occurring polypeptides or folds. These scaffolds may be derived from polypeptides of any species (or more than one species), such as humans, other mammals, other vertebrates, invertebrates, plants, bacteria, or viruses.

[0136] Typically, biocompatible framework structures are based on protein scaffolds or skeletons other than immunoglobulin domains. For example, those based on fibronectin, ankyrin, lipocalin, neocarzinostain, cytochrome b, CP1 zinc finger, PST1, coiled coil, LACI-D1, Z domain and tendamistat domain can be used (see, for example, Nygren and Uhlen, 1997, Current Opinion in Structural Biology, 7, 463-469).

[0137] Furthermore, in another embodiment, one skilled in the art will recognize that the antigen binding proteins described above may contain one or more of the heavy chain CDR1, CDR2, CDR3 and / or light chain CDR1, CDR2 and CDR3 with one or more amino acid substitutions, provided that the antibody retains the binding specificity of the unsubstituted CDR. The non-CDR portion of the antibody may be a non-protein molecule, where the binding agent cross-blocks the binding of the antibodies disclosed herein to human TSLP and / or inhibits TSLP activity. The non-CDR portion of the antibody may be a non-protein molecule, where the antibody exhibits a binding pattern to human TSLP protein similar to that exhibited by at least one of antibodies A1-A27 in a competitive binding assay and / or neutralizes the activity of TSLP. The non-CDR portion of the antibody can be composed of amino acids, where the antibody is a recombinant binding protein or synthetic peptide, which cross-blocks binding of the antibodies disclosed herein to human TSLP and / or neutralizes TSLP in vivo or in vitro. The non-CDR portion of the antibody can be composed of amino acids, where the antibody is a recombinant antibody, which exhibits a binding pattern to human TSLP polypeptide similar to that exhibited by at least one of antibodies A1-A27 in competitive binding assays and / or neutralizes the activity of TSLP.

[0138] A method for making antigen-binding proteins, especially antibodies.

[0139] As described above, an antigen-binding protein, such as an antibody, comprising one or more heavy chain CDR1, CDR2, CDR3, and / or light chain CDR1, CDR2 and CDR3 can be obtained by expression from a host cell comprising DNA encoding these sequences. The DNA encoding each CDR sequence can be determined based on the amino acid sequence of the CDR, and can be synthesized together with any desired antibody variable region framework and constant region DNA sequence using appropriate oligonucleotide synthesis techniques, site-directed mutagenesis and polymerase chain reaction (PCR) techniques. DNA encoding variable region frameworks and constant regions are widely available to those skilled in the art from gene sequence databases such as GenBank®.

[0140] Additional embodiments include chimeric antibodies (e.g., humanized versions of non-human (e.g., murine) monoclonal antibodies). Such humanized antibodies can be prepared by known techniques and offer the advantage of reduced immunogenicity when the antibodies are administered to humans. In one embodiment, a humanized monoclonal antibody contains the variable domain of a murine antibody (or all or part of its antigen binding site) and the constant domain from a human antibody. Alternatively, a humanized antibody fragment can contain the antigen binding site of a murine monoclonal antibody and a variable domain fragment (lacking the antigen binding site) from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies are described in Riechmann et al., 1988, Nature 332:323; Liu et al., 1987, Proc. Nat. Acad. Sci. USA 84:3439, Larrick et al., 1989, Bio / Technology 7:934, and Winter et al., 1993, TIPS 14:139. In one embodiment, the chimeric antibody is a CDR-grafted antibody. Techniques for humanizing antibodies are discussed, for example, in U.S. Patent Nos. 5,869,619, 5,225,539, 5,821,337, 5,859,205, and 6,881,557, Padlan et al., 1995, FASEB J. 9:133-39, and Tamura et al., 2000, J. Immunol. 164:1432-41. Additional techniques for producing such humanized antibodies are described in Zhang, W. et al., Molecular Immunology. 42(12):1445-1451, 2005; Hwang W. et al., Methods. 36(1):35-42, 2005; Dall'Acqua WF et al., Methods 36(1):43-60, 2005; and Clark, M., Immunology Today. 21(8):397-402, 2000).

[0141] Procedures have been developed to generate human or partially human antibodies in non-human animals. For example, mice have been generated in which one or more endogenous immunoglobulin genes have been inactivated by various methods. Human immunoglobulin genes have been introduced into the mouse to replace the inactivated mouse genes. Antibodies produced in the animal incorporate human immunoglobulin polypeptide chains encoded by the human genetic material introduced into the animal. In one embodiment, a non-human animal (e.g., a transgenic mouse) is immunized with a TSLP protein, such that antibodies directed against various TSLP polypeptides are generated in the animal. Examples of suitable immunogens are provided in the examples below.

[0142] Examples of techniques for the production and use of transgenic animals for the production of human or partially human antibodies can be found in U.S. Pat. Nos. 5,814,318, 5,569,825, and 5,545,806; Davis et al., 2003, Production of human antibodies from transgenic mice in Lo, ed. Antibody Engineering: Methods and Protocols, Humana Press, NJ:191-200; K ellermannら、2002,Curr Opin Biotechnol. 13:593~97.Russell.2000,Infect Immun. 68:1820~26、Cockら、2000,Eur J Immun. Rev. 30:534~40, Davis, 1999, Cancer Metastasis. 18:421~25、Green,1999,J Immunol Methods. 231:11~23、Jakobovits,1998,Advanced Drug Delivery Reviews 31:33~42、Greenら、1998,J Exp Med. 188:483~95;Jacobovits A,1998,Exp. Open. Invest. Drugs. 7:607~14, Tsuda, 1997, Genomics. 42:413~21.Mendez.1997,Night Genet. 15:146~56;Jacobovits,1994,Curr Biol. 4:761~63、Arbonesら、1994,Immunity. 1:247~60, Green, 1994, Nat Genet. 7:13~21, Jacobovits, 1993, Nature. 362:255~58;Jakobovitsら,1993,Proc Natl Acad Sci USA.90:2551~55; Huszar.“Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus.” International Immunology 5 (1993): 647–656, Choi et al., 1993, Nature Genetics 4: 117–23, Fishwild et al., 1996, Nature Biotechnology 14: 845–51, Harding et al., 1995, Annals of the New York Academy of Sciences, Lonberg et al., 1994, Nature 368:856~59, Lonberg, 1994, Transgenic Approaches to Human Monoclonal Antibodies in Handbook of Experimental Pharmacology 113: 49~101, Lonberg et al., 1995, Internal Review of Immunology 13:65~93, Neuberger, 1996, Nature Biotechnology 14:826, Taylor et al., 1992, Nucleic Acids Research 20: 6287-95, Taylor et al., 1994, International Immunology 6: 579-91, Tomizuka et al., 1997, Nature Genetics 16: 133-43, Tomizuka et al., 2000, Proceedings of the National Academy of Sciences USA 97: 722-27, Tuaillon et al., 1993, Proceedings of the National Academy of Sciences USA 90: 3720-24, and Tuaillon et al., 1994, Journal of Immunology 152: 2912-20.

[0143] In another aspect, the present invention provides a monoclonal antibody that binds to human TSLP. The monoclonal antibody can be produced using any technique known in the art (e.g., by immortalizing spleen cells taken from transgenic animals) after the completion of the immunization schedule. The spleen cells can be immortalized using any technique known in the art (e.g., by fusing them with myeloma cells to generate hybridoma cells). Myeloma cells for use in hybridoma generation fusion procedures preferably have enzyme deficiencies that do not produce antibodies, high fusion efficiency, and the inability of the myeloma cells to grow in a specific selection medium that supports the growth of only the desired fused cells (hybridomas). Examples of suitable cell lines for use in mouse fusions include Sp-20, P3- Examples of cell lines used in rat fusion include X63 / Ag8, P3-X63-Ag8.653, NS1 / 1.Ag 4 1, Sp210-Ag14, FO, NSO / U, MPC-11, MPC11-X45-GTG 1.7, and S194 / 5XX0 Bul; examples of cell lines used in rat fusion include R210.RCY3, Y3-Ag 1.2.3, IR983F, and 4B210. Other cell lines useful for cell fusion are U-266, GM1500-GRG2, LICR-LON-HMy2, and UC729-6.

[0144] In one embodiment, a hybridoma cell line is generated by immunizing an animal (e.g., a transgenic animal having human immunoglobulin sequences) with a TSLP immunogen; harvesting spleen cells from the immunized animal; fusing the harvested spleen cells with a myeloma cell line, thereby producing hybridoma cells; establishing a hybridoma cell line from the hybridoma cells; and identifying a hybridoma cell line that produces an antibody that binds a TSLP polypeptide. Such hybridoma cell lines, and the TSLP monoclonal antibodies produced by them, are encompassed by the invention.

[0145] Monoclonal antibodies secreted by hybridoma cell lines can be purified using any technique known in the art. Hybridomas or mAbs can be further screened to identify mAbs with specific properties, such as blocking TSLP activity, such as osteoprotegerin (OPG) production from primary human dendritic cells. Examples of such assays are provided in the Examples below.

[0146] Molecular evolution of the complementarity determining regions (CDRs) in the center of the antibody binding site has been used to isolate antibodies with increased affinity, for example, as described by Schier et al., J. Mol. Biol. 263:551. Thus, such techniques are useful in preparing antibodies against human TSLP.

[0147] Antigen binding proteins directed against human TSLP can be used, for example, in assays to detect the presence of TSLP, either in vitro or in vivo.

[0148] Although human, partially human, or humanized antibodies are suitable for many applications, particularly those involving administration of the antibody to a human subject, other types of antigen-binding proteins are suitable for certain applications. The non-human antibodies of the invention can be derived from any antibody-producing animal, such as, for example, mouse, rat, rabbit, goat, donkey, or non-human primate (monkey (e.g., cynomolgus or rhesus monkey) or ape (e.g., chimpanzee)). The non-human antibodies of the invention can be used, for example, in in vitro and cell culture-based applications, or in any other application in which an immune response against the antibodies of the invention does not occur, is insignificant, can be prevented, is unimportant, or is desired. In one embodiment, the non-human antibodies of the invention are administered to a non-human subject. In another embodiment, the non-human antibodies do not elicit an immune response in the non-human subject. In another embodiment, the non-human antibodies are derived from the same species as the non-human subject (e.g., a mouse antibody of the invention is administered to a mouse). Antibodies from a particular species can be made, for example, by immunizing an animal of that species with the desired immunogen, or by using artificial systems to produce antibodies of that species (e.g., bacterial or phage display based systems to produce antibodies of a particular species), or by converting an antibody from one species into an antibody from another species (e.g., by replacing the constant region of the antibody with the constant region from the other species), or by replacing one or more amino acid residues of the antibody so that it more closely resembles the sequence of an antibody from another species. In one embodiment, the antibody is a chimeric antibody that contains amino acid sequences derived from antibodies from two or more different species.

[0149] Antigen binding proteins can be prepared by any of a number of conventional techniques. For example, antigen binding proteins can be purified from cells that naturally express the antigen binding protein (e.g., antibodies can be purified from hybridomas that produce the antibodies) or can be produced in recombinant expression systems using any technique known in the art. For example, Monoclonal Antibodies, Hybridomas: A New Dimension In Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980); and Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1988).

[0150] Any expression system known in the art can be used to produce the recombinant peptides of the invention. Generally, a host cell is transformed with a recombinant expression vector containing DNA encoding the desired polypeptide. Among the host cells that can be used are prokaryotes, yeast or higher eukaryotic cells. Prokaryotes include gram-negative or gram-positive organisms, such as E. coli or Bacillus. Higher eukaryotic cells include insect cells and established cell lines of mammalian origin. An example of a suitable mammalian host cell line is the COS-7 strain of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., 1981, Cell 2000). 23:175), L cells, 293 cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, the BHK (ATCC CRL 10) cell line, and the CVI / EBNA cell line derived from the African green monkey kidney cell line CVI (ATCC CCL 70) as described by McMahan et al., 1991, EMBO J. 10: 2821. Suitable cloning and expression vectors for use in bacterial, fungal, yeast, and mammalian cell hosts are described by Pouwels et al., (Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985).

[0151] The transformed cells can be cultured under conditions that promote expression of the polypeptide, and the polypeptide is recovered by conventional protein purification procedures. One such purification procedure is described in the Examples below. Polypeptides contemplated for use herein include substantially homogeneous recombinant mammalian anti-TSLP antibody polypeptides that are substantially free of contaminating endogenous materials.

[0152] Antigen binding proteins can be prepared and screened for desired properties by any of a number of known techniques, some of which involve isolating a nucleic acid encoding the polypeptide chain (or a portion thereof) of an antigen binding protein of interest (e.g., a TSLP antibody) and manipulating that nucleic acid via recombinant DNA technology. The nucleic acid can be fused to another nucleic acid of interest or can be modified (e.g., by mutagenesis or other conventional techniques) to, for example, add, delete, or substitute one or more amino acid residues.

[0153] Single chain antibodies can be formed by linking heavy and light chain variable domain (Fv region) fragments via an amino acid bridge (a short peptide linker) to produce a single polypeptide chain. Such single chain Fvs (scFvs) consist of two variable domain polypeptides (V L and V H These polypeptides were prepared by fusing DNA encoding a peptide linker between DNA encoding the variable domains. The resulting polypeptides can fold back on themselves to form antigen-binding monomers or, depending on the length of the flexible linker between the two variable domains, can form multimers (e.g., dimers, trimers, or (Kortt et al., 1997, Prot. Eng. 10:423; Kortt et al., 2001, Biomol. Eng. 18:95-108). L and V HBy combining the containing polypeptides, multimeric scFvs that bind to different epitopes can be formed (Kriangkum et al., 2001, Biomol. Eng. 18:31-40). Techniques developed for the production of single-chain antibodies are described in U.S. Patent No. 4,946,778; Bird, 1988, Science 242:423; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879; Ward et al., 1989, Nature 334:544, de Graaf et al., 2002, Methods Mol Biol. 178:379-87. Single chain antibodies derived from the antibodies provided herein include, but are not limited to, scFvs comprising the variable domain combinations L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, and L27H27 encompassed by the invention.

[0154] Once synthesized, DNA encoding the antibody or fragment thereof of the present invention can be propagated and expressed by any of a variety of well-known methods for nucleic acid excision, ligation, transformation, and transfection using any number of known expression vectors. Thus, in certain embodiments, expression of the antibody fragment may be preferred in a prokaryotic host such as Escherichia.coli (see, e.g., Pluckthun et al., 1989 Methods Enzymol. 178:497-515). In certain other embodiments, expression of the antibody or fragment thereof may be preferred in eukaryotic host cells, including yeast (e.g., Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Pichia pastoris), animal cells (including mammalian cells), or plant cells. Examples of suitable animal cells include, but are not limited to, myeloma (e.g., mouse NSO strain), COS, CHO, or hybridoma cells. Examples of plant cells include tobacco, corn, soybean, and rice cells. One or more replicable expression vectors containing DNA encoding the variable and / or constant regions of the antibody can be prepared and used to transform a suitable cell line in which the production of the antibody occurs, for example a non-producing myeloma cell line such as the mouse NSO line, or bacteria such as E. coli. To obtain efficient transcription and translation, the DNA sequence in each vector contains appropriate control sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence. Specific methods for producing antibodies in this manner are generally well known and routinely used. For example, basic molecular biology procedures are described by Maniatis et al. (Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, New York, 1989; see also Maniatis et al., 3rd ed., Cold Spring Harbor Laboratory, New York, (2001)).DNA sequencing can be performed as described in Sanger et al. (PNAS 74:5463, (1977)) and in the Amersham International plc sequencing handbook, and site-directed mutagenesis can be performed using methods known in the art (Kramer et al., Nucleic Acids Res. 12:9441, (1984); Kunkel Proc. Natl. Acad. Sci. USA. 82:488-92 (1985); Kunkel et al., Methods in Enzymol. 154:367-82 (1987); the Anglian Biotechnology Ltd. handbook). In addition, numerous publications describe suitable techniques for preparing antibodies by DNA manipulation, constructing expression vectors, and transforming and culturing suitable cells (Mountain Acad. Sci., 2003, 144:131-132, 2003). and Adair, JR in Biotechnology and Genetic Engineering Reviews (ed. Tombs, MP, 10, Chapter 1, 1992, Intercept, Andover, UK); “Current Protocols in Molecular Biology”, 1999, FM Ausubel (ed.), Wiley Interscience, New York).

[0155] If it is desired to improve the affinity of an antibody according to the invention comprising one or more of the above CDRs, various techniques may be used to improve the affinity of the antibody, including the retention of the CDRs (Yang et al., J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al., Bio / Technology, 10, 779-783, 1992), the use of mutant strains of E. coli (Low et al., J. Mol. Biol., 250, 350-368, 1996), DNA shuffling (Patten et al., Curr. Opin. Biotechnol., 8, 724-733, 1997), phage display (Thompson et al., J. Mol. Biol., 256, 7-88, 1996) and PCR (Crameri, et al., Nature, 391, 288-291, These affinity maturation methods are discussed in detail in Vaughan et al. (Nature Biotechnology, 16, 535-539, 1998).

[0156] Other antibodies according to the invention can be obtained by conventional immunization and cell fusion procedures as described herein and known in the art. The monoclonal antibodies of the invention can be produced using a variety of known techniques. In general, monoclonal antibodies that bind to a particular antigen can be obtained by methods known to those skilled in the art (see, for example, Kohler et al., Nature 1999: 1133-1141, 1999). 256:495, 1975; Coligan et al., (eds.), Current Protocols in Immunology, 1:2.5.12.6.7 (John Wiley & Sons 1991); U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (eds.)(1980), and Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press (1988), Picksley et al., “Production of monoclonal antibodies against proteins expressed in E. coli,” in DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al., (eds.), page 93 (Oxford University Press 1995). Antibody fragments can be obtained therefrom using any suitable standard technique, such as proteolytic digestion, or by proteolytic digestion (e.g., with papain or pepsin), optionally followed by mild reduction and alkylation of disulfide bonds. Alternatively, such fragments can also be produced by recombinant genetic engineering techniques as described herein.

[0157] Monoclonal antibodies can be produced by infecting animals (e.g., rats, hamsters, rabbits, or mammals) with an immunogen comprising human TSLP of SEQ ID NO:2, other TSLP polypeptide sequences as described herein, or fragments thereof, by methods known in the art and described herein. or preferably mice (including, e.g., transgenic or knockout) as known in the art. The presence of specific antibody production can be monitored after the initial injection and / or after booster injections by taking serum samples and detecting the presence of antibodies or fragments thereof that bind to human TSLP using any one of several immunodetection methods known in the art and described herein. From animals producing the desired antibodies, lymphoid cells, most commonly cells from the spleen or lymph nodes, are harvested to obtain B lymphocytes. The B lymphocytes are then fused with a drug-sensitive myeloma cell fusion partner, preferably syngeneic with the immunized animal and optionally with other desired properties (e.g., unable to express endogenous Ig gene products, e.g., P3X63-Ag 8.653 (ATCC No. CRL 1580); NSO, SP20), to generate immortal eukaryotic cell lines, hybridomas.

[0158] Lymphoid (e.g., splenic) cells and myeloma cells can be combined in minutes using a membrane fusion promoter (e.g., polyethylene glycol or a non-ionic detergent) and seeded at low density on a selection medium that supports the growth of hybridoma cells but not unfused myeloma cells. A preferred selection medium is HAT (hypoxanthine, aminopterin, thymidine). After a sufficient time (usually about 1-2 weeks), colonies of cells are observed. Single colonies can be isolated and antibodies produced by the cells can be tested for binding activity to human TSLP using any one of a variety of immunoassays known in the art and described herein. The hybridomas are cloned (e.g., by limiting dilution cloning or by soft agar plaque isolation), and clones that produce antibodies specific to human TSLP are selected and cultured. Monoclonal antibodies from the hybridoma cultures can be isolated from the supernatant of the hybridoma cultures.

[0159] An alternative method for the production of mouse monoclonal antibodies is to inject the hybridoma cells into the peritoneal cavity of syngeneic mice (e.g., mice that have been treated (e.g., pristane-sensitized) to promote the formation of ascites fluid containing the monoclonal antibodies). Monoclonal antibodies can be isolated and purified by a variety of well-established techniques. Such isolation techniques include affinity chromatography with protein A, size-exclusion chromatography, and ion-exchange chromatography (see, e.g., Coligan, pp. 2.7.1-2.7.12 and 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," Methods in Molecular Biology, Vol. 10, pp. 79-104 (The Humana Press, Inc. 1992)). Monoclonal antibodies can be purified by affinity chromatography using an appropriate ligand selected based on the specific properties of the antibody (e.g., heavy or light chain isotype, binding characteristics, etc.). Examples of suitable ligands immobilized on a solid support include Protein A, Protein G, anti-constant region (light or heavy chain) antibodies, anti-idiotypic antibodies, and TSLP, or a fragment or variant thereof.

[0160] The antibody of the present invention is also a fully human monoclonal antibody. Fully human monoclonal antibodies can be generated by any number of techniques, such as those described above. Such methods further include, but are not limited to, Epstein-Barr Virus (EBV) transformation of human peripheral blood cells (including, for example, B lymphocytes), in vitro immunization of human B cells, fusion of spleen cells from immunized transgenic mice carrying inserted human immunoglobulin genes, isolation from a human immunoglobulin V-region phage library, or other procedures known in the art and based on the disclosure herein. For example, fully human monoclonal antibodies can be obtained from engineered transgenic mice that produce specific human antibodies in response to antigenic challenge. Methods for obtaining fully human antibodies from transgenic mice are described, for example, in Green et al., Nature Genet. 7:13, 1994; Lonberg et al., Nature 368:856, 1994; Taylor et al., Int. Immun. 6:579, 1994; U.S. Patent No. 5,877,397; Bruggemann et al., 1997 Curr. Opin. Biotechnol. 8:455-58; Jakobovits et al., 1995 Ann. NY Acad. Sci. 764:525-35. In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines carrying targeted disruptions of the endogenous heavy and light chain loci (see also Bruggemann et al., Curr. Opin. Biotechnol. 8:455-58 (1997)). For example, human immunoglobulin transgenes can be minigene constructs, or transloci on yeast artificial chromosomes, that undergo B cell-specific DNA rearrangement and hypermutation in mouse lymphoid tissues. Fully human monoclonal antibodies can be obtained by immunizing transgenic mice, which can then produce human antibodies specific for human TSLP. Lymphocytes of the immunized transgenic mice can be used to generate human antibody-secreting hybridomas by the methods described herein. Polyclonal sera containing fully human antibodies can also be obtained from the blood of the immunized animals.

[0161] One exemplary method for generating human antibodies of the invention involves immortalizing human peripheral blood cells by EBV transformation, as described, for example, in U.S. Patent No. 4,464,456. Such immortalized B cell lines (or lymphoblastoid cell lines) that produce monoclonal antibodies that specifically bind to human TSLP can be identified by immunodetection methods (e.g., ELISA) as provided herein, and then isolated by standard cloning techniques. The stability of lymphoblastoid cell lines that produce anti-TSLP antibodies can be improved by fusing the transformed cell lines with mouse myelomas according to methods known in the art (see, for example, Glasky et al., Hybridoma 8:377-89 (1989)) to generate mouse-human hybrid cell lines. Yet another method for generating human monoclonal antibodies is in vitro immunization, which involves priming human splenic B cells with human TSLP, followed by fusing the primed B cells with a heterohybrid fusion partner. See, e.g., Boerner et al., 1991 J. Immunol. 147:86-95.

[0162] In certain embodiments, B cells producing anti-human TSLP antibodies are selected and the light and heavy chain variable regions are cloned from the B cells by molecular biology techniques known in the art (WO 92 / 02551; U.S. Patent No. 5,627,052; Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-48 (1996)) and described herein. B cells from immunized animals can be isolated from spleens, lymph nodes, or peripheral blood samples by selecting cells that produce antibodies that specifically bind to TSLP. B cells can also be isolated from humans (e.g., peripheral blood samples). Methods for detecting single B cells that produce antibodies with desired specificity (e.g., by plaque formation, fluorescence-activated cell sorting, detection of specific antibodies after in vitro stimulation, etc.) are well known in the art. Methods for selection of B cells producing specific antibodies include, for example, preparing a single suspension of B cells in soft agar containing human TSLP. Binding of a specific antibody produced by a B cell to an antigen results in the formation of a complex that can be seen as an immunoprecipitate. After B cells producing the desired antibody are selected, the specific antibody gene can be cloned by isolating and amplifying the DNA or mRNA by methods known in the art and described herein.

[0163] A further method for obtaining the antibodies of the present invention is by phage display. See, e.g., Winter et al., 1994 Annu. Rev. Immunol. 12:433 -55; see Burton et al., 1994 Adv. Immunol. 57:191-280. Combinatorial libraries of human or mouse immunoglobulin variable region genes can be created in phage vectors which can be screened to select Ig fragments (Fab, Fv, sFv, or multimers thereof) that specifically bind to TSLP or variants or fragments thereof. See, e.g., U.S. Patent No. 5,223,409; Huse et al., 1989 Science 246:1275-81; Sastry et al., Proc. Natl. Acad. Sci. USA 86:5728-32 (1989); Alting-Mees et al., Strategies in Molecular Biology 3:1-9 (1990); Kang et al., 1991 Proc. Natl. Acad. Sci. USA 88:4363-66; Hoogenboom et al., 1992 J. Molec. Biol. 227:381-388; Schlebusch et al., 1997 Hybridoma 16:47-52 and references cited therein. For example, a library containing a large number of polynucleotide sequences encoding Ig variable region fragments can be inserted into the genome of a filamentous bacteriophage, such as M13 or a variant thereof, in frame with a sequence encoding the phage coat protein. The fusion protein can be a fusion of the coat protein with the light chain variable region domain and / or the heavy chain variable region domain. According to certain embodiments, immunoglobulin Fab fragments can also be displayed on a phage particle (see, e.g., U.S. Patent No. 5,698,426).

[0164] A heavy or light chain immunoglobulin cDNA expression library can be prepared, for example, from λlmmunoZap TM (H) and λImmunoZap TM(L) vector (Stratagene, La Jolla, California). Briefly, mRNA is isolated from a B cell population and used to generate heavy and light chain immunoglobulin cDNA expression libraries in the λImmunoZap(H) and λImmunoZap(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., supra; see also Sastry et al., supra). Positive plaques are then converted to a non-lytic plasmid, allowing high level expression of monoclonal antibody fragments from E. coli.

[0165] In one embodiment, the variable regions of the genes expressing the monoclonal antibody of interest in a hybridoma are amplified using nucleotide primers. These primers can be synthesized by one of skill in the art or purchased from commercially available sources (e.g., V Ha , V Hb , V Hc , V Hd , C H1 , V L and C L (See Stratagene (La Jolla, California), which sells primers for mouse and human variable regions, including primers for the .alpha. and .alpha. regions.) These primers can be used to amplify the heavy or light chain variable regions, respectively, which are then used in ImmunoZAP amplification. TM H or ImmunoZAP TM L (Stratagene). These vectors can then be introduced into E. coli, yeast, or mammalian-based systems for expression. H and V L Large amounts of single-chain proteins, including fusions of domains, can be produced using these methods (see Bird et al., Science 242:423-426, 1988).

[0166] Once a cell producing an antibody according to the invention has been obtained, using any of the immunization and other techniques described above, the specific antibody gene can be cloned by isolating and amplifying the DNA or mRNA from the cell according to standard methods as described herein. Antibodies produced from the cells can be sequenced, and the CDRs identified and the DNA coding for those CDRs can be manipulated as described above to produce other antibodies according to the invention.

[0167] The antigen binding proteins of the invention preferably modulate TSLP activity in one of the cell-based assays described herein and / or in one of the in vivo assays described herein, and / or cross-block the binding of one of the antibodies described herein, and / or are cross-blocked from binding to TSLP by one of the antibodies described herein. Particularly useful are antigen binding proteins that cross-compete with one of the exemplary antibodies described herein (i.e., cross-block the binding of one of the exemplary antibodies described herein and are cross-blocked from binding to TSLP by one of the exemplary antibodies). Thus, such binding agents can be identified using the assays described herein.

[0168] In certain embodiments, antibodies are generated by first identifying antibodies that bind to TSLP and / or neutralize in the cell-based assays described herein and / or cross-block the antibodies described herein and / or are cross-blocked from binding to TSLP by one of the antibodies described herein. The CDR regions from these antibodies are then inserted into a suitable biocompatible framework to generate an antigen-binding protein. The non-CDR portion of the binding agent may be composed of amino acids or may be a non-protein molecule. The assays described herein allow for characterization of the binding agent. Preferably, the binding agent of the present invention is an antibody as defined herein.

[0169] The antigen binding proteins of the present invention include proteins that bind to the same epitope as the exemplary antibodies described herein. As discussed in Example 9, epitopes can be structural or functional. A structural epitope can be thought of as the patch of the target that is covered by the antibody. A functional epitope includes residues that are part of the structural epitope and directly contribute to the affinity of the interaction (e.g., hydrogen bonds, ionic interactions). One way to determine the epitope of an antibody is by scanning mutations in the target molecule and measuring the effect of the mutations on binding. Given the three-dimensional structure of the antibody binding region, mutations in the epitope can decrease or increase the binding affinity of the antibody to the mutated target.

[0170] Antigen-binding proteins can be defined by their epitopes. As seen in Table 6, the antibodies can all bind to TSLP, but they are affected differently by mutations of specific residues in TSLP, indicating that their respective epitopes do not completely overlap. Preferred antigen-binding proteins include proteins that share at least a portion of the structural epitopes of the reference antibodies described herein.

[0171] For example, a preferred antigen binding protein is one that shares at least a portion of the same structural epitope with A2. This is evidenced by an increase in binding affinity compared to wild-type TSLP when TSLP has the following mutations: K67E, K97E, K98E, R100E, K101E, or K103E. This can also be evidenced by a decrease in binding affinity compared to wild-type TSLP when TSLP has the following mutations: K21E, T25R, S28R, S64R, K73E. Although the antigen binding protein and A2 may be similarly affected by some mutations and not by others, the more identity there is between the antigen binding protein and A2 in the effect of mutations at specific residues in TSLP, the more the antigen binding protein and the reference antibody share a structural epitope.

[0172] Another preferred antigen binding protein is a protein that shares at least a portion of the same structural epitope as A4. This is because TSLP has the following structural epitopes: K97E, K98E, R100E, K This is evidenced by increased binding affinity compared to wild-type TSLP when TSLP has a K10E, A14R, K21E, D22R, K73E, K75E, or A76R mutation.

[0173] Another preferred antigen binding protein is one that shares at least a portion of the same structural epitope as A5, as can be evidenced by a decrease in binding affinity compared to wild-type TSLP, where TSLP has a K12E, D22R, S40R, R122E, N124E, R125E, or K129E mutation.

[0174] Another preferred antigen binding protein is one that shares at least a portion of the same structural epitope as A6, as can be evidenced by a decrease in binding affinity when TSLP has an S40R, S42R, H46R, R122E, or K129E mutation compared to wild-type TSLP.

[0175] Another preferred antigen binding protein is one that shares at least a portion of the same structural epitope as A7. This is evidenced by an increase in binding affinity when TSLP has a K101E mutation compared to wild-type TSLP. This can also be evidenced by a decrease in binding affinity when TSLP has a D2R, T4R, D7R, S42R, H46R, T49R, E50R, Q112R, R122E, R125E, or K129E mutation compared to wild-type TSLP.

[0176] Another preferred antigen-binding protein is one that shares at least a portion of the same structural epitope as A10. This is evidenced by an increase in binding affinity compared to wild-type TSLP when TSLP has a K97E, K98E, R100E, K101E, or K103E mutation. This can also be evidenced by a decrease in binding affinity compared to wild-type TSLP when TSLP has a N5R, S17R, T18R, K21E, D22R, T25R, T33R, H46R, A63R, S64R, A66R, E68R, K73E, K75E, A76R, A92R, T93R, Q94R, or A95R mutation.

[0177] Another preferred antigen-binding protein is one that shares at least a portion of the same structural epitope as A21. This is evidenced by an increase in binding affinity compared to wild-type TSLP when TSLP has a K97E, K98E, R100E, K101E, or K103E mutation. This may also be evidenced by a decrease in binding affinity compared to wild-type TSLP when TSLP has a K21E, K21R, D22R, T25R, T33R, S64R, K73E, K75E, E111R, or S114R mutation.

[0178] Another preferred antigen binding protein is one that shares at least a portion of the same structural epitope as A23. This is evidenced by an increase in binding affinity compared to wild-type TSLP when TSLP has a K67E, K97E, K98E, R100E, K101E, or K103E mutation. This may also be evidenced by a decrease in binding affinity compared to wild-type TSLP when TSLP has an E9R, K10E, K12E, A13R, S17R, S20R, K21E, K21R, K73E, K75E, N124E, or R125E mutation.

[0179] Another preferred antigen binding protein is one that shares at least a portion of the same structural epitope as A26. This is evidenced by increased binding affinity when TSLP has a K97E, K98E, R100E, K101E, or K103E mutation compared to wild-type TSLP. This is also evidenced by increased binding affinity when TSLP has a A14R, K21E, D22R, A63R, S64R, K67E, K73E, A76R, A92R, or A95R mutation compared to wild-type TSLP. If so, this can be evidenced by a decrease in binding affinity compared to wild-type TSLP.

[0180] Comparing mutations that affect binding between antibodies suggests that certain residues in TSLP are likely to be part of the antibody's ability to bind TSLP and interfere with TSLP activity. Such residues include K21, D22, K73, and K129. Thus, preferred antigen binding proteins include proteins that have a higher affinity for wild-type TSLP than for TSLP containing a K21E mutation, proteins that have a higher affinity for wild-type TSLP than for TSLP containing a D21R mutation, proteins that have a higher affinity for wild-type TSLP than for TSLP containing a K73E mutation, and proteins that have a higher affinity for wild-type TSLP than for TSLP containing a K129E mutation.

[0181] Furthermore, many of the exemplary antigen binding proteins described herein share the property that when the basic patch of amino acids at positions 97-103 is changed to acidic amino acids, the affinity for TSLP is increased.

[0182] nucleic acid In one aspect, the invention provides isolated nucleic acid molecules, including, for example, polynucleotides encoding all or a portion of an antigen binding protein (e.g., one or both chains of an antibody of the invention, or fragments, derivatives, muteins, or variants thereof), polynucleotides sufficient for use as hybridization probes, PCR or sequencing primers to identify, assay, mutate, or amplify polynucleotides encoding a polypeptide, antisense nucleic acids to inhibit expression of a polynucleotide, and complementary sequences of the foregoing. The nucleic acids may be of any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1,000, 1,500, 3,000, 5,000 or more nucleotides in length, and / or can include one or more additional sequences (e.g., regulatory sequences), and / or can be part of a larger nucleic acid (e.g., a vector). The nucleic acids can be single-stranded or double-stranded and can include RNA and / or DNA nucleotides, as well as variants thereof (e.g., peptide nucleic acids).

[0183] Nucleic acids encoding antibody polypeptides (e.g., heavy or light chains, variable domains only, or full length) can be isolated from B cells of mice immunized with TSLP antigen. The nucleic acids can be isolated by conventional methods such as polymerase chain reaction (PCR).

[0184] Nucleic acid sequences encoding the variable regions of the heavy and light chain variable regions are set forth above. One of skill in the art will appreciate that due to the degeneracy of the genetic code, each polypeptide sequence disclosed herein is encoded by a large number of other nucleic acid sequences. The present invention provides each degenerate nucleotide sequence encoding each antigen binding protein of the present invention.

[0185] The present invention further provides a nucleic acid that hybridizes to another nucleic acid (e.g., a nucleic acid comprising any of the nucleotide sequences A1 to A27) under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. See, for example, Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989) 6.3.1-6.3.6. As defined herein, moderately stringent hybridization conditions are 5x sodium chloride / sodium citrate (SCC), 0.5% SDS, 1.0 mM Hybridization in prewash solution containing EDTA (pH 8.0), approximately 50% formamide A typical hybridization condition uses a hybridization buffer, 6×SSC, and a hybridization temperature of 55° C. (or other similar hybridization solution, e.g., a hybridization solution containing about 50% formamide at a hybridization temperature of 42° C.), and wash conditions in 0.5×SSC, 0.1% SDS at 60° C. One stringent hybridization condition is hybridization in 6×SSC at 45° C., followed by one or more washes in 0.1×SSC, 0.2% SDS at 68° C. Moreover, one of skill in the art can manipulate the hybridization and / or wash conditions to increase or decrease the stringency of hybridization, such that nucleic acids containing nucleotide sequences at least 65, 70, 75, 80, 85, 90, 95, 98 or 99% identical to each other will generally remain hybridized to each other. Basic parameters influencing the selection of hybridization conditions and guidance for devising suitable conditions are set forth, for example, by Sambrook, Fritsch and Maniatis (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11; and Current Protocols in Molecular Biology, 1995, Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4) and can be readily determined by one of skill in the art, based, for example, on the length and / or base composition of the DNA.

[0186] Changes can be introduced into a nucleic acid by mutation, resulting in a change in the amino acid sequence of a polypeptide (e.g., an antigen binding protein) that it encodes. Mutations can be introduced using any technique known in the art. In one embodiment, one or more specific amino acid residues are altered, e.g., using a site-directed mutagenesis protocol. In another embodiment, one or more randomly selected residues are altered, e.g., using a random mutagenesis protocol. However produced, the mutant polypeptides can be expressed and screened for desired properties.

[0187] Mutations can be introduced into a nucleic acid without significantly altering the biological activity of the polypeptide it encodes. For example, nucleotide substitutions can be made that result in amino acid substitutions at non-essential amino acid residues. In one embodiment, the nucleotide sequence given herein for A1-A27, or a desired fragment, variant, or derivative thereof, is mutated to encode an amino acid sequence that includes one or more deletions or substitutions of the amino acid residues set forth herein for A1-A27, such that two or more sequences result in different residues. In another embodiment, mutagenesis inserts an amino acid residue adjacent to one or more amino acid residues set forth herein for A1-A27, such that two or more sequences result in different residues. Alternatively, one or more mutations can be introduced into a nucleic acid that selectively alter the biological activity (e.g., binding to TSLP) of the polypeptide it encodes. For example, the mutations can quantitatively or qualitatively alter the biological activity. Examples of quantitative changes include increasing, decreasing, or eliminating the activity. Examples of qualitative changes include altering the antigen specificity of the antigen binding protein.

[0188] In another aspect, the present invention provides nucleic acid molecules suitable for use as primers or hybridization probes for the detection of nucleic acid sequences of the present invention. The nucleic acid molecules of the present invention may contain only a portion of a nucleic acid sequence encoding a full-length polypeptide of the present invention, e.g., a fragment that can be used as a probe or primer, or a fragment that encodes an active portion of a polypeptide of the present invention (e.g., a TSLP-binding portion).

[0189] Probes based on the sequences of the nucleic acids of the invention can be prepared by cloning the nucleic acids or similar nucleic acids (e.g., The probe may be used to detect a transcript encoding a polypeptide of the present invention. The probe may contain a label group (e.g., a radioisotope), a fluorescent compound, an enzyme, or an enzyme co-factor). Such a probe may be used to identify cells expressing the polypeptide.

[0190] In another aspect, the present invention provides a vector comprising a nucleic acid encoding a polypeptide of the present invention or a portion thereof. Examples of vectors include, but are not limited to, plasmids, viral vectors, non-episomal mammalian vectors, and expression vectors (e.g., recombinant expression vectors).

[0191] The recombinant expression vector of the present invention may contain the nucleic acid of the present invention in a form suitable for expression of the nucleic acid in a host cell. The recombinant expression vector contains one or more control sequences selected based on the host cell used for expression, which are operably linked to the nucleic acid sequence to be expressed. Control sequences include control sequences that direct constitutive expression of a nucleotide sequence in many types of host cells (e.g., SV40 early gene enhancer, Rous sarcoma virus promoter and cytomegalovirus promoter), control sequences that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific control sequences (see Voss et al., 1986, Trends Biochem. Sci. 11:287, Maniatis et al., 1987, Science 236:1237, the entire contents of which are incorporated herein by reference)), and control sequences that direct inducible expression of a nucleotide sequence in response to a specific treatment or condition (e.g., metallothionein promoter in mammalian cells and tet-responsive and / or streptomycin-responsive promoters in both prokaryotic and eukaryotic systems (see ibid.)). One skilled in the art will understand that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into a host cell to thereby produce a protein or peptide, including a fusion protein or peptide, encoded by a nucleic acid as described herein.

[0192] In another aspect, the present invention provides a host cell into which the recombinant expression vector of the present invention is introduced. The host cell can be any eukaryotic cell (e.g., E. coli) or eukaryotic cell (e.g., yeast, insect, or mammalian cell (e.g., CHO cell)). The vector DNA can be introduced into prokaryotic or eukaryotic cells via common transformation or transfection techniques. For stable transfection of mammalian cells, it is known that only a small number of cells can integrate foreign DNA into their genome, depending on the expression vector and transfection technique used. To identify and select these integrants, a gene encoding a selection marker (e.g., for resistance to antibiotics) is generally introduced into the host cell along with the gene of interest. Preferred selection markers include genes that confer resistance to drugs (e.g., G418, hygromycin, and methotrexate). Cells stably transfected with the introduced nucleic acid can be identified by drug selection, in addition to other methods (e.g., cells that have incorporated the selection marker gene survive, while other cells die).

[0193] Indications TSLP is involved in promoting a variety of inflammatory disorders, particularly allergic inflammatory disorders. As used herein, the term "allergic inflammation" refers to the development of immunoglobulin E (IgE)-associated immune responses (Manual of Allergy and Immunology, Chapter 2, Alvin M. Sanico, Bruce S. Bochner, and Sarbjit S. Saini, Adelman et al., ed., Lippincott, Williams, Wilkins, Philadelphia, PA, (2002)). As used herein, Allergic inflammation is mediated by the influx of type 2 helper T cells (T HAllergic inflammation is generally characterized by the invasion of inflammatory cells (inflammatory cytokines, inflammatory cytokines, and inflammatory cytokines) by the immune system (Kay, supra). Allergic inflammation includes inflammatory skin conditions such as atopic dermatitis, as well as allergic sinusitis, pulmonary inflammatory diseases such as asthma, and allergic conjunctivitis (Manual of Allergy and Immunology, supra. As used herein, the term "TSLP-associated allergic inflammation" refers to allergic inflammatory conditions in which TSLP is upregulated or has otherwise been demonstrated to be involved.

[0194] Allergic asthma is a chronic inflammatory disease of the airways characterized by airway eosinophilia, high levels of serum IgE, and mast cell activation associated with airway hyperresponsiveness, epithelial damage, and mucus hypersecretion (Wills-Karp, M, Ann. Rev. Immunol. 17:255-281 (1999), Manual of Allergy and Immunology, supra). Studies have shown that varying degrees of chronic inflammation are present in all asthmatic airways, even during symptom-free periods. In susceptible individuals, this inflammation causes recurrent symptoms of wheezing, shortness of breath, chest tightness, and coughing (Manual of Allergy and Immunology, supra).

[0195] Atopic dermatitis is a chronic pruritic skin disease characterized by skin damage and elevated serum total IgE, eosinophilia, and increased release of histamine from basophils and mast cells. Individuals with atopic dermatitis have a pronounced T H 2 response, and the initiation of atopic dermatitis lesions is marked by T cells releasing high levels of IL-4, IL-5 and IL-13. HThis is thought to be mediated by early cutaneous infiltration of TSLP-.2 lymphocytes (Leung, J. Allergy Clin Immunol 105:860-76 (2000)). The relationship between TSLP and other inflammatory cytokines is described in U.S. Patent Application Serial No. 11 / 205,904, Publication No. 2006 / 0039910, which is incorporated herein by reference.

[0196] Human TSLP expression, as detected by in situ hybridization, was reported to increase in asthmatic airways in correlation with disease severity (Ying et al., J. Immunology 174:8183-8190 (2005)). Assays of TSLP mRNA levels in lung samples from asthmatic patients showed increased expression of TSLP compared to controls. In addition, TSLP protein levels are detectable in concentrated bronchoalveolar lavage (BAL) fluids from asthmatic, lung transplant, and cystic fibrosis patients. TSLP has recently been found to be released in response to microbes and trauma, as well as inflammation, and to activate mast cells (Allakhverdi et al., J Exp. Med 20492: 253-258 (2007)).

[0197] Human TSLP protein has been shown to be disease-associated in bronchial mucus and BAL fluid from patients with moderate / severe asthma and COPD (Ying et al., J Immunol 181(4):2790-8 (2008)).

[0198] Overexpression of TSLP in the lungs of transgenic mice results in asthma-like airway inflammation (Zhou et al., Nat. Immunol 10:1047-1053 (2005)). In addition, it has been reported that TSLPR-deficient mice do not develop asthma in an OVA-asthma model, indicating that TSLP is required for the development of asthma in an airway inflammation model (Zhou et al., supra; Carpino et al., Mol. Cell Biol. 24:2584-2592 (2004)).

[0199] In addition to asthma, elevated levels of TSLP protein and mRNA have been found in epithelial cells of affected skin and inflamed tonsils of patients with atopic dermatitis (AD). (Soumelis et al., Nature Immunol: 3 (7): 673-680 (2002)). Overexpression of TSLP in the skin of transgenic mice results in an AD-like phenotype (Yoo et al., J Exp Med 202:541-549 (2005)).

[0200] Thus, TSLP antagonists, particularly the TSLP antigen binding proteins and antibodies of the present application, are useful as therapeutic treatments for allergic inflammation, particularly asthma and atopic dermatitis.

[0201] In addition, TSLP antagonists, particularly the TSLP antigen-binding proteins and antibodies of the present disclosure, are also useful for treating fibrotic disorders. TSLP has been shown to be involved in promoting fibrotic disorders, as described in Application Serial No. 11 / 344,379. TSLP has been found to induce fibroblast accumulation and collagen deposition in animals. For example, intradermal injection of mouse TSLP into mice resulted in fibrosis in the subcutaneous tissue of the mice, characterized by fibroblast proliferation and collagen deposition. Antagonizing TSLP activity prevented or reduced fibroblast proliferation and collagen deposition in the tissue.

[0202] As used herein, the term "fibroproliferative disease" or "fibrotic disease or disorder" refers to a condition associated with fibrosis in one or more tissues. As used herein, the term "fibrosis" refers to the formation of fibrous tissue as a reparative or reactive process, rather than as a normal component of an organ or tissue. Fibrosis is characterized by the accumulation of fibroblasts and collagen deposition above normal deposition in any particular tissue. As used herein, the term "fibrosis" is used interchangeably with "fibroblast accumulation and collagen deposition." Fibroblasts are connective tissue cells and are distributed throughout connective tissues throughout the body. Fibroblasts secrete a loose extracellular matrix that contains type I and / or type III collagen. In response to injury to a tissue, nearby fibroblasts migrate to the wound, proliferate, and produce large amounts of collagenous matrix. Collagen is a fibrous protein rich in glycine and proline, and is the major component of the extracellular matrix and connective tissue, cartilage, and bone. Collagen molecules are triple-stranded helical structures called α-chains that are wound around each other in a rope-like spiral. Collagen exists in several forms or types, of which type I, the most common, is found in skin, tendons, and bones; and type III, found in skin, blood vessels, and internal organs.

[0203] Fibrotic disorders include, but are not limited to, systemic and localized scleroderma, keloids and hypertrophic scars, atherosclerosis, restenosis, pulmonary inflammation and fibrosis, idiopathic pulmonary fibrosis, liver cirrhosis, fibrosis as a result of chronic hepatitis B or C infection, kidney disease, heart disease resulting from scar tissue, and eye diseases such as macular degeneration, retinal and vitreal retinopathy. Additional fibrotic disorders include fibrosis due to chemotherapy agents, radiation-induced fibrosis, and injury and burns.

[0204] Scleroderma is a fibrotic disorder characterized by thickening and hardening of the skin due to the overproduction of new collagen by fibroblasts in the skin and other organs. Systemic sclerosis can affect multiple organs. Systemic sclerosis is characterized by hyalinized and thickened collagenous fibrous tissue with thickening of the skin and adhesion to the underlying tissue, especially on the hands and face. The disease may also be characterized by loss of peristalsis and dysphagia due to submucosal fibrosis of the esophagus, difficulty in breathing due to pulmonary fibrosis, fibrosis of the myocardium, and vascular alterations in the kidneys (Stedman's Medical Dictionary, 26 th Edition, Williams & Wilkins, 1995). Pulmonary fibrosis affects 30-70% of patients with scleroderma and often results in restrictive lung disease (Atamas et al., Cytoplasmic fibrosis). Kine and Growth Factor Rev 14: 537-550 (2003)). Idiopathic pulmonary fibrosis is a chronic, progressive, and usually fatal lung disorder thought to be the result of a chronic inflammatory process (Kelly et al., Curr Pharma Design 9: 39-49 (2003)).

[0205] Thus, TSLP antagonists, particularly the TSLP antigen binding proteins and antibodies of the present application, are useful as therapeutic treatments for fibrotic diseases, including, but not limited to, scleroderma, interstitial lung disease, idiopathic pulmonary fibrosis, fibrosis resulting from chronic hepatitis B or chronic hepatitis C, radiation-induced fibrosis, and fibrosis resulting from wound healing.

[0206] Although the above indications are preferred, other diseases, disorders, or conditions may be amenable to treatment or may be prevented by administration of the antigen conjugate to a subject. Such diseases, disorders, and conditions include inflammation, autoimmune diseases, inflammation of cartilage, fibrotic diseases and / or bone degradation, arthritis, rheumatoid arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathy-based arthritis, juvenile reactive arthritis, juvenile Reter's syndrome, SEA syndrome (seronegative, enthesopathy, arthropathic syndrome), juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset juvenile rheumatoid arthr ... psoriatic arthritis, onset) rheumatoid arthritis, ankylosing spondylitis, enteropathy-based arthritis, reactive arthritis, Reter's syndrome, SEA syndrome (seronegative, enthesopathy, arthropathy syndrome), dermatomyositis, psoriatic arthritis, scleroderma, systemic lupus erythematosus, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodosa, Wegener's granulomatosis, arteritis, polymyalgia rheumatica, sarcoidosis, scleroderma, sclerosis, primary cholesteatosis , sclerosing cholangitis, Sjogren's syndrome, psoriasis, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, dermatitis, atopic dermatitis, atherosclerosis, lupus, Still's disease, systemic lupus erythematosus (SLE), myasthenia gravis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac disease, multiple sclerosis (MS), asthma, COPD, Guillain-Barre disease, type I diabetes, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, GVHD, etc. In certain embodiments, a pharmaceutical composition comprising a therapeutically effective amount of a TSLP antigen binding protein is provided.

[0207] The term "treatment" includes alleviation or prevention of at least one symptom or other aspect of a disorder, or reducing the severity of a disease, and the like. An antigen binding protein need not provide a complete cure or eradicate every symptom or symptom of a disease to constitute a potential therapeutic. As recognized in the relevant art, an agent used as a therapeutic may reduce the severity of a given disease state, but need not eliminate every symptom of the disease to be considered a useful therapeutic. Similarly, a treatment administered prophylactically need not be completely effective in preventing the onset of a condition to constitute a potential therapeutic. It is sufficient to simply reduce the impact of a disease (e.g., by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or to reduce the likelihood that a disease will develop or worsen in a subject. One embodiment of the present invention relates to a method comprising administering an antigen binding protein to a patient in an amount and for a time sufficient to induce a sustained improvement over baseline in an index reflecting the severity of a particular disorder.

[0208] Pharmaceutical Compositions In some embodiments, the present invention provides a method for administering a therapeutically effective amount of one or more antigen binding proteins of the present invention in a pharmaceutical composition, comprising administering to a patient ... The present invention also provides pharmaceutical compositions comprising the compound of formula (I) and / or a combination thereof, together with an adjuvant. Additionally, the present invention provides methods of treating a patient by administering such pharmaceutical compositions. The term "patient" includes human and animal subjects.

[0209] Pharmaceutical compositions comprising one or more antigen binding proteins can be used to reduce TSLP activity. Pharmaceutical compositions comprising one or more antigen binding proteins can be used in the treatment of consequences, symptoms, and / or pathologies associated with TSLP activity. Pharmaceutical compositions comprising one or more antigen binding proteins can be used in methods of inhibiting TSLP binding to and / or signaling with TSLPR, comprising providing TSLP with the antigen binding proteins of the present invention.

[0210] In certain embodiments, acceptable formulants are preferably non-toxic to recipients at the dosages and concentrations employed. In certain embodiments, the pharmaceutical compositions may contain formulants to modify, maintain or preserve, for example, pH, osmolality, viscosity, clarity, color, isotonicity, flavor, sterility, stability, rate of dissolution or release, absorption or penetration of the composition.In such embodiments, suitable formulants include amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (e.g., borate, bicarbonate, Tris-HCl, citrate, phosphate, or other organic acids); bulking agents (e.g., phosphate ... agents) (e.g., mannitol or glycine); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)); complexing agents (e.g., caffeine, polyvinylpyrrolidone, beta cyclodextrin or hydroxypropyl beta cyclodextrin); bulking agents; monosaccharides; disaccharides; and other carbohydrates (e.g., glucose, sucrose, mannose or dextrin); proteins (e.g., serum albumin, gelatin or immunoglobulins); colorants, flavors and diluents; emulsifiers; hydrophilic polymers (e.g., polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (e.g., sodium); preservatives (e.g., benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben , chlorhexidine, sorbic acid or hydrogen peroxide); solvents (e.g., glycerin, propylene glycol or polyethylene glycol); sugar alcohols (e.g., mannitol or sorbitol); suspending agents; surfactants or wetting agents (e.g., pluronic, PEG, sorbitan esters, polysorbates (e.g., polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancers (e.g., sucrose or sorbitol); tonicity enhancers (e.g., alkali metal halides, preferably sodium chloride or potassium chloride, mannitol, sorbitol); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants. See REMINGTON'S PHARMACEUTICAL SCIENCES, 18'' Edition, (AR Genrmo, ed.), 1990, Mack Publishing Company.

[0211] In certain embodiments, optimal pharmaceutical compositions are determined by those of skill in the art depending, for example, on the intended route of administration, the mode of delivery, and the desired dose. See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, supra. In certain embodiments, such compositions may affect the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the antigen binding proteins of the present invention. In certain embodiments, the first vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier may be water for injection, physiological salt solution, or artificial cerebrospinal fluid, possibly supplemented with other substances common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. In certain embodiments, Pharmaceutical compositions include Tris buffer at about pH 7.0-8.5, or acetate buffer at about pH 4.0-5.5, and may further include sorbitol or a suitable substitute thereof. In certain embodiments of the invention, TSLP antigen binding protein compositions may be prepared for storage by mixing selected compositions with optimal formulation agents (REMINGTON'S PHARMACEUTICAL SCIENCES, supra) at the desired degree of purity in the form of lyophilized mass or aqueous solution. Additionally, in certain embodiments, the TSLP antigen binding protein product may be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0212] The pharmaceutical composition of the present invention may be selected for parenteral delivery. Alternatively, the composition may be selected for inhalation or delivery through the digestive tract (e.g., orally). The formulation components are preferably present in concentrations that are acceptable to the site of administration. In certain embodiments, a buffer is used to maintain the composition within a physiological pH or a slightly lower pH, generally within a pH range of about 5 to about 8. Including about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, and about 8.0.

[0213] When parenteral administration is contemplated, therapeutic compositions for use in the present invention may be provided in the form of a parenterally acceptable aqueous solution containing the desired TSLP antigen binding protein in a pyrogen-free, pharma- ceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which the TSLP antigen binding protein is formulated as sterile, isotonic, and properly preserved. In certain embodiments, the preparation may include a formulation of the desired molecule with an agent that can provide controlled or sustained release of the product that can be delivered via depot injection (e.g., injectable microspheres, bio-erodible particles, polymeric compounds (e.g., polylactic acid or polyglycolic acid), beads, or liposomes). In certain embodiments, hyaluronic acid, which has the effect of enhancing duration in the circulation, may also be used. In certain embodiments, an implantable drug delivery device may be used to introduce the desired antigen binding protein.

[0214] The pharmaceutical compositions of the present invention may be formulated for inhalation. In these embodiments, the TSLP antigen binding protein may be conveniently formulated as a dry, inhalable powder. In certain embodiments, the TSLP antigen binding protein inhalation solution may also be formulated with a propellant for aerosol delivery. In certain embodiments, the solution may be nebulized. Pulmonary administration and formulation methods therefor are further described in International Patent Application No. PCTUS94 / 001875, which is incorporated by reference and describes pulmonary delivery of chemically modified proteins.

[0215] It is also contemplated that the formulations may be administered orally. TSLP antigen binding proteins administered in this manner may be formulated with or without carriers customarily used in compounding solid dosage forms such as tablets and capsules. In certain embodiments, capsules are designed to release the active portion of the formulation in the gastrointestinal tract just before bioavailability is maximized and pre-systemic degradation is minimized. Additional agents may be included to facilitate absorption of the TSLP antigen binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrants, and binders may also be used.

[0216] Pharmaceutical compositions of the invention are preferably provided containing an effective amount of one or more TSLP antigen binding proteins in a mixture with non-toxic excipients suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit dose form.

[0217] Suitable excipients include, but are not limited to, inert diluents (e.g., calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate); or binders (e.g., starch, gelatin, or acacia); or lubricants (e.g., magnesium stearate, stearic acid or talc).

[0218] Additional pharmaceutical compositions will be apparent to those skilled in the art, including formulations that include TSLP antigen binding proteins in sustained or controlled delivery formulations. Methods for formulating a variety of other sustained or controlled delivery methods (e.g., liposome carriers, bioerodible microparticles or perforated beads, and depot injections) are also known to those skilled in the art. See, for example, International Patent Application No. PCT / US93 / 00829, which is incorporated by reference and describes the controlled release of perforated polymeric microparticles for the delivery of pharmaceutical compositions.

[0219] Sustained-release preparations may include semipermeable polymeric materials in the form of shaped articles, eg, films, or microcapsules. Sustained release preparations may include polyesters, hydrogels, polylactides (disclosed in U.S. Pat. No. 3,773,919 and European Patent Publication No. EP 058481, each incorporated by reference), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., 1983, Biopolymers 2:547-556), poly(2-hydroxyethyl-inethacrylate) (Langer et al., 1981, J. Biomed. Mater. Res. 15:167-277 and Langer, 1982, Chem. Tech. 12:98-105), ethylene vinyl acetate (Langer et al., 1981, supra), or poly-D(-)-3-hydroxybutyrate (European Patent Publication No. EP 133,988).

[0220] Sustained release compositions can also include liposomes, which can be prepared by any of several methods known in the art.See, for example, Eppstein et al., 1985, Proc. Natl Acad. ScL USA 82.3688-3692; European Patent Application Publication No. EP 036,676; European Patent Application Publication No. EP 088,046 and European Patent Application Publication No. EP 143,949, which are incorporated by reference.

[0221] Pharmaceutical compositions used for in vivo administration are generally provided as sterile preparations. Sterilization can be achieved by filtration through a sterile filter membrane. If the composition is lyophilized, sterilization using this method can be carried out either before or after lyophilization and reconstitution. Compositions for parenteral administration can be stored in lyophilized form or in solution. Parenteral compositions are generally placed in a container with a sterile access port (for example, an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle).

[0222] Aspects of the invention include self-buffered TSLP antigen binding protein formulations, which can be used as pharmaceutical compositions as described in International Patent Application WO 06138181 A2 (PCT / US2006 / 022599). WO 0613818 1 A2 (PCT / US2006 / 022599) is incorporated herein by reference in its entirety. One embodiment provides a self-buffered TSLP antigen binding protein formulation comprising a TSLP antigen binding protein, the formulation having a total salt concentration of less than 150 mM.

[0223] The therapeutically effective amount of a pharmaceutical composition containing a TSLP antigen binding protein may be used, for example, For example, the dosage will depend on the therapeutic situation and objectives. Those of skill in the art will appreciate that appropriate dosage levels for treatment will vary depending, in part, on the molecule being delivered, the indication for which the TSLP antigen binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and / or condition (age and general health) of the patient.

[0224] In certain embodiments, the clinician can titrate the dosage and vary the route of administration to obtain optimal therapeutic effects. A typical dosage can vary from about 0.1 μg / kg to about 30 mg / kg or more depending on the factors mentioned above. In certain embodiments, the dosage can vary from 0.1 μg / kg to about 30 mg / kg, optionally from 1 μg / kg to about 30 mg / kg, or from 10 μg / kg to about 5 mg / kg.

[0225] The frequency of administration depends on the pharmacokinetic parameters of the particular TSLP antigen binding protein in the formulation used.Generally, the clinician administers the composition until a dose is reached that achieves the desired effect.The composition can therefore be administered as a single dose, or as two or more doses over a period of time (which may or may not contain the same amount of the desired molecule), or as continuous infusion via an implanted device or catheter.Further refinement of the appropriate dose is routinely made by those skilled in the art, and is within the scope of the work performed by those skilled in the art.

[0226] Appropriate dosages can be ascertained through the use of appropriate dose-response data. In certain embodiments, the antigen binding proteins of the invention can be administered to patients over extended periods of time. Long-term administration of the antigen binding proteins of the invention minimizes adverse immune or allergic responses commonly associated with antigen binding proteins that are not fully human (e.g., antibodies raised against human antigens in non-human animals, e.g., non-fully human antibodies or non-human antibodies produced in non-human species).

[0227] The route of administration of the pharmaceutical composition is according to known methods (e.g., orally, via injection by intravenous, intraperitoneal, intracerebral (intracemdrome), intraventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release system or by implantation device). In certain embodiments, the composition may be administered by bolus or by infusion, or by implantation device.

[0228] The compositions may also be administered locally via the implantation of a membrane, sponge, or another suitable material into which the desired molecule has been absorbed or encapsulated. In certain embodiments in which an implantation device is used, the device may be implanted into a suitable tissue or organ, and delivery of the desired molecule may be via diffusion, time-release bolus, or continuous administration.

[0229] Combination therapy In a further embodiment, the antigen binding protein is administered in combination with other agents useful for treating the condition from which the patient is afflicted. Examples of such agents include both proteinaceous and non-proteinaceous agents. When multiple therapies are administered simultaneously, the dosage may be adjusted accordingly, as recognized in the relevant art. "Co-administration" and combination therapy are not limited to co-administration, but also include treatment regimes in which the antigen binding protein is administered at least once during a course of treatment that includes administering at least one other therapeutic agent to the patient. EXAMPLES

[0230] The invention having been described, the following examples are offered by way of illustration and not by way of limitation.

[0231] Example 1: Antigen Preparation Several forms of recombinant TSLP were used as immunogens. Human TSLP was expressed in both E. coli and mammalian cells. The E. coli-produced human TSLP was a full-length protein with no tags. A TSLP protein was produced in COS PKB cells with a deletion of the furin cleavage site, generated by deleting nucleotides 382-396 (AGAAAAAGGAAAGTC, SEQ ID NO:370), which corresponds to amino acids 128-132 (RKRKV, SEQ ID NO:371). This protein contains a C-terminal poly-HIS-Flag tag (nucleotide sequence = ATGTTCCCTTTTGCCTTACTATATGTTCTGTCAGTTTCTTTCAGGAAAATCTTCATCTTACAACTTGTAGGGCTGGTGTTAACTTACGACTTCACTAACTGTGACTTTGAGAAGATTAAAGCAGCC TATCTCAGTACTATTTCTAAAGACCTGATTACATATATGAGTGGGACCAAAAGTACCGAGTTCAACAACACCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACCTTC AATCCCACCGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGCCATGAAAACTAAGGCTGCCTTAGCTATCTGGTGCCCAGGCTATTCGGAAACTCAGATAAATGCTACTCAGGCAATGAAGAAG AGGACAACCAATAAATGTCTGGAACAAGTGTCACAATTACAAGGATTGTGGCGTCGCTTCAATCGACCTTTACTGAAACAACAGCATCACCATCACCATCACGACTACAAAGACGATGACGACAAA (SEQ ID NO:372); Protein sequence = MFPFALLYVLSVSFRKIFILQLVGLVLTYDFTNCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRTTNKCLEQVSQLQGLWRRFNRPLLKQQHHHHHHDYKDDDDK (SEQ ID NO: 373).

[0232] In a separate campaign, a C-terminal poly-HIS-Flag tagged full-length TSLP protein was produced in COS PKB cells (nucleotide sequence: ATGTTCCCTTTTGCCTTACTATATGTTCTGTCAGTTTCTTTCAGGAAAATCTTCATCTTACAACTTGTAGGGCTGGTGTTAACTTACGACTTCACTAACTGTGACTTTGAGAAGATTAAAGCAGCCTAT CTCAGTACTATTTCTAAAGACCTGATTACATATATGAGTGGGACCAAAAGTACCGAGTTCAACAACACCGTCTCTTGTAGCAATCGGCCACATTGCCTTACTGAAATCCAGAGCCTAACCTTCAATCCCA CCGCCGGCTGCGCGTCGCTCGCCAAAGAAATGTTCGCCATGAAAACTAAGGCTGCCTTAGCTATCTGGTGCCCAGGCTATTCGGAAACTCAGATAAATGCTACTCAGGCAATGAAGAAGAGGAGAAAAAAGGAAAGTCACAACCAATAAATGTCTGGAACAAGTGTCACAATTACAAGGATTGTGGCGTCGCTTCAATCGACCTTTACTGAAACAACAGCATCACCATCACCATCACGACTACAAAGACGATGACGACAAA (SEQ ID NO:374); protein sequence = MFPFALLYVLSVSFRKIFILQLVGLVLTYDFTNCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLQGLWRRFNRPLLKQQHHHHHHDYKDDDDK (SEQ ID NO:375)). Note that amino acid sequence 1-28 (MFPFALLYVLSVSFRKIFILQLVGLVLT, SEQ ID NO:376) is the signal peptide that is cleaved from the mature products of both of these proteins.

[0233] In addition, cynomolgus TSLP was cloned and sequenced with nucleotides 358-372 (AGAAAAAGGAAAGTC), which correspond to the furin cleavage site (amino acids 120-124 (RKRKV, SEQ ID NO: 371)), fused to the same C-terminal poly-HIS-Flag. , SEQ ID NO: 370) was deleted (DNA =ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACCGGTTACGACTTCACTAACTGTGACTTTCAGAAGATTGAAGCAGACTATCTCCGTACTATTTCTAAAGACCTGATTACATATATGAGTGGGACTAAAAGTACCGACTTCAACAACACCGTCTCCTGTAGCAATCGGCCACACTGCCTTACTGAAATCCAGAGCCTAACCTTCAATCCCACCCCC CGCTGCGCGTCGCTCGCCAAGGAAATGTTCGCCAGGAAAACTAAGGCTACCCTCGCTCTCTGGTGCCCAGGCTATTCGGAAACTCAGATAAATGCTACTCAGGCAATGAAGAAGAGGACAACCAATAAATGTCTGGAACAAGTGTCACAATTACTAGGATTGTGGCGTCGCTTCATTCGAACTTTACTGAAACAACAGCACCACCACCACCACCATGACTATAAAGACGATGACGACAAAT (SEQ ID NO:377); protein= METDTLLLWVLLLWVPGSTGYDFTNCDFQKIEADYLRTISKDLITYMSGTKSTDFNNTVSCSNRPHCLTEIQSLTFNPTPRCASLAKEMFARKTKATLALWCPGYSETQINATQAMKKRTTNKCLEQVSQLLGLWRRFIRTLLKQQHHHHHHDYKDDDDK (SEQ ID NO: 378)) or as full length / natural product (nucleotide sequence = ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACCGGTTACGACTTCACTAACTGTGACTTTCAGAAGATTGAAGCAGACTATCTCCGTACTATTTCTAAAGACCTGATTACATATATGAGTGGGACTAAAAGTACCGACTTCAACAACACCGTCTCCTGTAGCAATCGGCCACACTGCCTTACTGAAATCCAGAGCCTAACCTTCAAT CCCACCCCCCGCTGCGCGTCGCTCGCCAAGGAAATGTTCGCCAGGAAAACTAAGGCTACCCTCGCTCTCTGGTGCCCAGGCTATTCGGAAACTCAGATAAATGCTACTCAGGCAATGAAGAAGAGGAGAAAA AGGAAAGTCACAACCAATAAATGTCTGGAACAAGTGTCACAATTACTAGGATTGTGGCGTCGCTTCATTCGAACTTTACTGAAACAACAGCACCACCACCACCACCATGACTATAAAAGACGATGACGACAAA (SEQ ID NO:379); protein=METDTLLLWVLLLWVPGSTGYDFTNCDFQKIEADYLRTISKDLITYMSGTKSTDFNNTVSCSNRPHCLTEIQSLTFNPTPRCASLAKEMFARKTKATLALWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLLGLWRRFIRTLLKQQHHHHHHDYKDDDDK (SEQ ID NO:380) and subcloned and expressed in COS PKB cells.Note that the amino acid sequence 1-20 (METDTLLLWVLLLWVPGSTG, SEQ ID NO:381) is the signal peptide that is cleaved from the mature products of both of these cyno proteins.

[0234] Example 2 Mouse anti-human TSLP antibody hTSLP-Fc was used to immunize Balb / c mice (Jackson Laboratories, Bar Harbor, Maine). After several rounds of immunization, lymphocytes were released from the spleen and fused with mouse myeloma cells NS1 (ATCC) by chemical fusion using 50% PEG / DMSO (Sigma). The fused cells were incubated in 10% FBS, 5% Origen Cloning Factor (BioVe) and 10% DMSO (Sigma). ris TM ), 2 × 10 cells in 200 μl of DMEM HAT (0.1 mM hypoxanthine, 0.16 mM thymidine, 4 mM aminopterin, Sigma) medium supplemented with 1× penicillin-streptomycin-glutamine, sodium pyruvate (Invitrogen). 4 The cells were seeded in a 96-well plate at a density of 100 cells / well. Seven days after fusion, the medium was changed to 10% FBS, 5% Origen Cloning Factor (BioVeris TM The medium was replaced with DMEM HT (0.1 mM hypoxanthine, 0.16 mM thymidine) supplemented with 1× penicillin-streptomycin-glutamine, sodium pyruvate (Invitrogen). Conditioned medium was collected two days after medium change and preceded the first screening.

[0235] Example 3: Generation of fully human antibodies Fully human monoclonal antibodies specific for TSLP can be produced as described, for example, in US 2005 / 0118643, U.S. Pat. Nos. 6,114,598, 6,162,963, 7,049,426, 7,064,244, Green et al., Nature Genetics 7:13-21 (1994); Medez et al., Nature Genetics 15:146-156 (1997); Green and Jakobovitis J. Ex. Med. 188:483-495 (1998), all of which are incorporated herein by reference, using XenoMouse® technology and as described below.

[0236] Two campaigns were performed. In campaign 1, the IgG2 and IgG4 cohorts of XenoMouse® were used. 50% of the mice received E. coli-produced human TSLP and 50% received mammalian-produced human TSLP (above). Serum titers were monitored by ELISA (below), and the mice with the best titers were fused to generate hybridomas using the following method.

[0237] Selected mice were sacrificed and draining lymph nodes were harvested and pooled from each cohort. Lymph node cells were enriched for B cells, and the B cells were fused with myeloma cells to generate hybridomas. The fused hybridoma lines were then plated in hybridoma medium and cultured at 37°C for 10-14 days. The hybridoma supernatants were screened by ELISA for IgG antibodies that bind TSLP, as described below.

[0238] A second campaign was initiated in which two cohorts of IgG2 XenoMouse® were immunized with mammalian produced human TSLP and one cohort was boosted with cynomolgus TSLP. After several rounds of immunization, lymphocytes from lymph nodes were fused and cultured as described above. After culture, hybridoma supernatants were screened for binding to TSLP by ELISA as described below.

[0239] Polyclonal supernatants from both campaigns were selected for further subcloning based on the assays described below. Hybridomas containing antibodies that are potential inhibitors of TSLP activity were identified and cross-reactivity with cynomolgus TSLP was further determined. The results are shown in Example 5 below. Promising hybridoma supernatants were selected based on performance in the primary DC assay described below. The hybridomas were single cell cloned and expanded for further testing. Antibodies were then purified as described below.

[0240] Antibodies were purified from hybridoma conditioned medium using Mab Select (GE Healthcare) resin. 100 μl of a 1:2 slurry of Mab Select resin equilibrated in PBS was added to between 7 and 10 ml of conditioned medium (CM). The tubes were placed on a rotator at 4-8°C overnight. The tubes were centrifuged at 1,000 x g for 5 min to remove non-specific antibodies. The bound fraction was decanted. The resin was washed with 5 ml PBS and centrifuged as above and decanted. The resin was then transferred to a SPIN-X, 0.45 μm, 2 ml tube. The resin was washed twice more with 0.5 ml PBS and centrifuged. Mabs were eluted with 0.2 ml 0.1 M acetic acid by incubating for 10 min at room temperature with occasional mixing. The tube was centrifuged and 30 μl of 1 M Tris buffer, Ph 8.0 was added to the eluate. Purified Mabs were stored at 4-8°C.

[0241] Example 4: Antibody Assays A. ELISA to detect the presence of anti-TSLP antibodies ELISAs were performed by coating Costar 3368 medium-binding 96-well plates with recombinantly produced wtHuTSLP or pHisFlag at 2 μg / ml in 1× PBS / 0.05% azide, 50 μl / well, and incubating overnight at 4° C. The plates were washed and blocked with 250 μl of 1× PBS / 1% milk (assay diluent) and incubated at room temperature for at least 30 minutes.

[0242] Approximately 50 μl / well of hybridoma supernatant, positive control mouse antibody M385, or negative control was added and incubated for 2 hours at room temperature. The plates were washed and secondary antibody goat anti-human IgG Fc HPR (Pierce) or alternatively goat anti-mouse IgG HPR (Jackson Labs) was applied at 400 ng / ml in assay diluent. The plates were incubated for 1 hour at room temperature, washed, and the OD was read at 450 nm.

[0243] B Screening of anti-TSLP hybridoma supernatants was performed using one of the following functional assays.

[0244] 1. 96-well plates were coated with soluble huIL-7Ra-huTSLPR-Fc protein with an 8 amino acid linker (SGGAPMLS, SEQ ID NO:382) between the receptor and human Fc and incubated overnight at 4°C.

[0245] 2. The plates were washed and blocked with PBS + 1% BSA + 5% sucrose for 1 hour at room temperature.

[0246] 3. The plates were incubated with biotinylated huTSLPHFdel (HF stands for polyHis Flag, where TSLP has a deleted furin cleavage site) (del). The plates were then incubated with (+ / -) hybridoma supernatants or mouse anti-human TSLP (M385) as a positive control for 2 hours at room temperature.

[0247] 4. SA-HRP detection (streptavidin-horseradish peroxidase). SA binds tightly to the biotin moiety of biotinylated huTSLPHFdel, and HRP catalyzes the oxidation of the chromogen TMB by hydrogen peroxide (turning blue).

[0248] B. Cell-Based Assays 1) Inhibition of TSLP-induced proliferation of a stable BAF cell line expressing the human TSLPR-IL7R complex by hybridoma supernatants or purified antibodies was determined by the following protocol.

[0249] 1. BAF in growth medium (RPMI 1640 + 10% FBS + 1% L-glutamine + 0.1% Pen / Strep + 0.1% 2-ME): Hu TSLPR stable cell lines were washed to remove TSLP used in the maintenance medium (same as growth medium but with the addition of 10 ng / mL huTSLPHFwt).

[0250] 2. HuTSLPwtpHF (+ / -) or cynomolgus TSLPwtpHF (+ / -) were incubated in wells with hybridoma supernatants / purified antibodies / or mouse anti-human TSLP (M385) for 30 minutes at room temperature.

[0251] 3. 5×10 4 Cells / well were added and incubated for 3 days.

[0252] 4. The cells were pulsed with tritiated thymidine (1 uCi / well) overnight. The proliferation or inhibition of the BAF cells was evaluated by the amount of tritiated thymidine incorporation (CPM) by the cells.

[0253] 2) Primary cell assay. Inhibition of TSLP-induced osteoprotegerin (OPG) (described in U.S. Pat. No. 6,284,728) production from primary human dendritic cells by hybridoma or purified antibodies was determined by the following protocol.

[0254] 1. Peripheral blood CD11c+ myeloid DCs were enriched from normal in house donor leukapheresis packs using a CD1c(BDCA-1) DC isolation kit (Miltenyi Biotec).

[0255] 2. huTSLPwtpHF (+ / -) or cynomolgus TSLPwtpHF were incubated with supernatant or purified antibody or mouse anti-human TSLP for 30 minutes at room temperature.

[0256] 3.1×105 cells / well were added and incubated for 48 hours. Supernatants were harvested and assayed for human OPG production by ELISA, and inhibition of OPG production by hybridoma supernatants or purified antibodies was determined. OPG ELISA was performed using R&D systems DuoSet® development kit. Anti-TSLP antibodies inhibited OPG production from cells in a dose-dependent manner.

[0257] 3) Cynomolgus monkey peripheral blood mononuclear cell assay. Inhibition of CynoTSLP-induced CCL22 / MDC production by hybridoma supernatants or purified antibodies was determined by the following protocol.

[0258] 1. Peripheral blood mononuclear cells (PBMCs) were obtained from peripheral blood obtained from cynomolgus monkeys (SNBL) by overlaying a 1:1 blood:PBS mixture onto isolymph.

[0259] 2. Cynomolgus TSLPwtpHF(+ / -) supernatant / purified antibody or soluble huIL-7Ra-huTSLPR-Fc were incubated at room temperature for 30 minutes.

[0260] 3. 4×10 5Cells / well were added and incubated for 5 days. The supernatants were harvested and assayed for cynomolgus CCL22 / MDC production by ELISA.

[0261] Example 5: K D Decision The surface plasmon resonance experiments described in this patent application were carried out at 25° C. using a Biacore 3000 instrument (Biacore International AB, Uppsala, Sweden) equipped with a CM4 sensor chip. Anti-Fcγ-specific capture antibodies were covalently immobilized to two flow cells on the CM4 chip using standard amine coupling chemistry with HBS-EP as the running buffer. Briefly, each flow cell was activated with a 1:1 (v / v) mixture of 0.1 M NHS and 0.4 M EDC. AffiniPure goat anti-human IgG, Fcγ fragment-specific antibody (Jackson ImmunoResearch Inc. West Grove, VA, USA) was used. PA) was immobilized at 30ug / ml in 10mM sodium acetate, pH 5.0 onto two flow cells at a target level of 3,000RU. Remaining reactive surfaces were deactivated with an injection of 1M ethanolamine. The running buffer was then switched to HBS-EP + 0.1mg / ml BSA for all remaining steps.

[0262] The following antibodies were tested: A5 IgG2 is a purified clonal antibody, A2 IgG1 and IgG2 are recombinant purified antibodies, and A3 IgG4 and A4 IgG4 are clonal supernatants. Antibodies were appropriately diluted in running buffer such that a 2 min injection at 10 μl / min over the test flow cell resulted in approximately 110-175 response units of antibody captured on the test flow cell surface. No antibody was captured on the control flow cell surface. Various concentrations of human, cynomolgus, or murine TSLP were then run over the two flow cells along with a buffer blank. The concentration ranges for human and cynomolgus TSLP are 0.44-100 nM, while the concentration range for murine TSLP is 8.2-6000 nM. A flow rate of 50 μl / min was used, and a 2 min association phase was followed by a 10-30 min dissociation phase. After each cycle, the surface was regenerated with a 30 second injection of 10 mM glycine pH 1.5. Fresh antibody was then captured onto the test flow cell in preparation for the next cycle.

[0263] Data were double-referenced by subtracting the control surface response to remove bulk refractive index changes and the average buffer blank response to remove systematic artifacts from the experimental flow cells. TSLP data were processed and globally fit to a 1:1 interaction model with local Rmax in BIA evaluation Software v 4.1. (Biacore International AB, Uppsala, Sweden). Association (k a ) and dissociation (k d ) rate constant and the dissociation equilibrium constant (K D ) were used to calculate the dissociation rate constants and dissociation equilibrium constants are summarized in the table found in Example 6.

[0264] Example 6: In vitro activity of antibodies The following antibodies were characterized for kd and KD using the Biacore assay described above. Primary dendritic cell assays were used to determine IC50 (pM). Data for A5 was generated using purified clonal antibody, data for A2 was generated using recombinant purified antibody, and data for A3 and A4 was generated using clonal supernatants. All variants of TSLP were produced from mammalian cells.

[0265] [Table 4-1] Example 7: Recombinant expression and purification of antibodies Development of stable cell lines expressing antibodies Overlapping oligonucleotides were synthesized to correspond to the primary sequences of the light and heavy chain variable domains of both the sense and antisense strands. This oligonucleotide pool was used in a standard PCR. The products from this first reaction were used as templates in a second PCR amplification. The amplified variable heavy and variable light chain fragments were subcloned into intermediate vectors and sequenced to identify error-free products. The variable heavy chain fragment was cloned into a transient expression vector containing a signal peptide and human IgG2 constant region. The variable light chain fragment was cloned into a transient expression vector containing a signal peptide and human lambda constant region. The complete heavy chain gene was transferred into vector pDC324. The complete light chain gene was transferred into expression vector pDC323.

[0266] The CS-9 host cells used for transfection of the anti-TSLP expression plasmids are a CHO cell line derived from DXB-11 cells through adaptation to serum-free medium (Rasmussen et al., Cytotechnology 28:31-42, 1998). The anti-TSLP cell line was generated by transfecting CS-9 host cells with the expression plasmids pDC323-anti-TSLP-lambda and pDC324-anti-TSLP-IgG2 using standard electroporation or lipofection procedures. After transfection of the host cell line with the expression plasmids, the cells were grown in selective medium for 2-3 weeks to allow for selection of the plasmids and recovery of the cells. In some cases, the medium was supplemented with 3% dialyzed fetal bovine serum (ds or dFBS). If serum was used, after the selection period, the serum was removed from the medium. The cells were grown in selective medium until they achieved greater than 85% viability. This pool of transfected cells was then cultured in culture medium.

[0267] Cell line cloning A cell bank of selected clones was generated by the following procedure. The cloning step ensured that a clonal population and cell bank were generated that would allow reproducible implementation in commercial manufacturing. The amplified pool of antibody-expressing cells was seeded under limiting dilution in 96-well plates, and candidate clones were evaluated for their ability to grow and be productive in small-scale studies.

[0268] Example 8: Antibody Cross-Competition A common method for defining epitopes is through competition experiments. Antibodies that compete with each other may be considered to bind to the same site on the target. This example describes a method for determining competition for binding to TSLP and the results of this method when applied to many of the antibodies described herein.

[0269] Binning experiments can be performed in many ways, and the method used can have a certain effect on the assay results. What these methods have in common is that typically TSLP is bound by one reference antibody and probed by the other. If the reference antibody interferes with the binding of the probe antibody, then these antibodies are said to be in the same bin. The order in which these antibodies are used is important. When antibody A is used as a reference antibody and it blocks the binding of antibody B, the reverse is not always true: antibody B used as a reference antibody does not necessarily block antibody A. There are many factors at play here: binding of an antibody may cause a conformational change in the target that interferes with the binding of a second antibody, or epitopes that overlap but do not completely occlude each other may allow the second antibody to still have a high affinity interaction with the target sufficient to allow binding. An antibody with a much higher affinity may have a higher ability to bump the blocking antibody without getting in the way. Generally, if competition is observed in either order, the antibodies are said to be binned together, and if both antibodies can block each other, their epitopes are likely to overlap more completely.

[0270] For this example, a modification of the Multiplexed Binning method described by Jia et al. (J. Immunological Methods, 288 (2004) 91-98) was used. Because the presence of a furin cleavage site in TSLP can lead to heterogeneity in TSLP protein preps, TSLP was used in which the arginine in the furin cleavage site was mutated to alanine. See U.S. Patent No. 7,288,633. Streptavidin-coated Luminex beads of each bead code (Luminex, #L100-L1XX-01, where XX designates the bead code) were incubated in 100 ul of 6 pg / bead biotinylated monovalent mouse anti-human IgG capture antibody (BD Pharmingen, #555785) for 1 hour at room temperature in the dark, then washed three times with PBSA (phosphate buffered saline (PBS) + 1% bovine serum albumin (BSA)). Each bead code was separately incubated with 100ul of a 1:10 dilution of anti-TSLP antibody (Coating Antibody) for 1 hour and then washed. The beads were pooled and then distributed into a 96-well filter plate (Millipore, #MSBVN1250). 100ul of 2ug / ml parental TSLP was added to half of the wells and buffer was added to the other half and incubated for 1 hour and then washed. 100ul of a 1:10 dilution of anti-TSLP antibody (Detection Ab) was added to one well with TSLP and one well without TSLP and incubated for 1 hour and then washed. An irrelevant human IgG (Jackson, #009-000-003) and a no antibody condition (blank) were run as negative controls. 20ul of PE-conjugated monovalent mouse anti-human IgG (BD Pharmingen, #555787) was added to each well. The beads were incubated for 1 hour and then washed. The beads were resuspended in 75ul PBSA and at least 100 events per bead code were collected on a BioPlex instrument (BioRad).

[0271] The median fluorescence intensity (MFI) of antibody pairs without TSLP was subtracted from the signal of the corresponding reaction containing TSLP. For antibodies that bound simultaneously and therefore were considered to be in different bins, the values ​​of the reactions had to meet two criteria: 1) their values ​​should be twice that of the coating antibody paired with itself, an irrelevant antibody, or the blank, whichever was highest, and 2) their values ​​should be greater than the signal of the detection antibody present with the irrelevant or blank coated beads.

[0272] Analysis of the competition between the above antibodies was complicated by the fact that there was a discrepancy between the performance of the antibodies as probes versus their performance as blockers. However, when considering only antibody bins that were distinct (i.e., each antibody blocks the other when used as a reference), a minimum of eight bins was found, as shown in Table 4 below.

[0273] [Table 4-2] It is noted that some antibodies (such as A23 and A6) were found to be in multiple bins. Other binning associations could be determined, and the inclusion or exclusion of antibodies from these bins was biased towards exclusion.

[0274] The results of this assay determined which other antibodies cross-competed for binding with the reference antibody. By "cross-competing for binding" it is meant that the reference antibody, when used as a blocking antibody, was able to block the binding of the other antibody, when used as a probe, and vice versa. In other words, if the reference antibody was able to block the other antibody, but the other antibody was not able to block the reference antibody, then those antibodies were not said to cross-compete. A list of cross-competing antibodies is provided in Table 5.

[0275] [Table 5] Example 9: Epitope Mapping Although epitopes are often thought of as linear sequences, more often antibodies recognize surfaces of targets that are composed of discontinuous amino acids. These amino acids may be far from a linear sequence, but may be close together through target folding, and antibodies that recognize such epitopes are known as conformation-sensitive or simply conformational antibodies. This type of binding can be defined by the use of denaturing Western blots, in which the target is heated in the presence of detergents and reducing agents to unfold the target before running on a gel. Blots from this gel can then be probed with antibodies, and antibodies that are able to recognize the target after this treatment likely recognize linear epitopes. Epitopes for antibodies that bind linear sequences can be defined by binding to peptides (e.g., PepSpot), but conformational antibodies are not expected to bind standard peptides with high affinity.

[0276] Reduced, heat-denatured, purified parent TSLP protein was loaded onto a 10% Bis-Tris Nupage gel in MES SDS running buffer. Proteins were transferred to PVDF membranes blocked with 5% nonfat dry milk (NFDM) in PBS+0.05% Tween (PBST) and incubated with TSLP antibody for 1 h at RT. The blots were washed three times with PBST and then incubated with goat anti-huIgG secondary antibody for 1 h at RT. The blots were washed again and incubated with anti-goat IgG:Alexa 680. After washing three times with PBST, the blots were scanned on a LiCo to visualize the bands.

[0277] Antibodies A2, A4, A5, A6, A7, A10, A21, A23 and A26 were characterized using this method. Antibodies A2, A4 and A5 bound to linear epitopes as evidenced by strong bands on Western blots. All other antibodies were conformational due to the absence or very weak bands on Western blots.

[0278] Epitopes can be further defined as structurally or functionally. Functional epitopes are generally a subset of structural epitopes and are composed of residues that directly contribute to the affinity of the interaction (e.g., hydrogen bonds, ionic interactions). Structural epitopes are those that are specifically targeted by antibodies. The target can be thought of as a patch of the target covered by

[0279] Scanning mutagenesis is used to further define the epitope bound by the antibody. Often alanine scanning mutagenesis is used to define functional epitopes; substitution of alanine (methyl side chain) is essentially a truncation of the wild-type amino acid side chain and is extremely subtle. Interactions with the protein backbone (such as hydrogen bonding to amide linkages) are often eliminated using alanine scanning. Instead, systematic mutagenesis of arginine and glutamic acid was used. These two side chains were chosen because of their large steric bulk and charge, which allows mutations that occur in structural epitopes and have a larger effect on antibody binding. Arginine was generally used except when the WT residue was arginine or lysine, in which case the residue was mutated to glutamic acid to switch the charge. In a few cases, the WT residue was mutated to both arginine and glutamic acid.

[0280] 95 amino acids distributed throughout TSLP were selected for mutation to arginine or glutamic acid. Because hydrophobic residues are generally found inside the folded core of proteins, selection was biased toward charged or polar amino acids to reduce the possibility of mutations resulting in misfolded proteins. In the absence of a crystal structure, these residues were essentially selected randomly and were distributed throughout TSLP. TSLP was used that contained a mutated furin cleavage site as described in Example 8.

[0281] BIOPLEX TM A binding assay was used to measure binding of anti-TSLP antibodies to mutant TSLP. Biotinylated Penta-His Ab (Qiagen, Lot No: 130163339) was conjugated to 100 bead-coded streptavidin-coated beads (Luminex, #L100-L1XX-01, where XX designates the bead code). These were used to capture his-tagged proteins. The 100 bead code allowed multiplexing of all 85 mutants, 3 parental controls, an unrelated protein, and 12 blanks. Binding of the antibodies to the mutant proteins was compared to binding of the antibodies to the parent.

[0282] 100ul of 1:5 dilution of TSLP mutants and parent in the supernatant, as well as 1ug / mL purified TSLP WT, 1ug / mL irrelevant or no protein, were allowed to bind to the coated beads for 1 hour at RT with vigorous shaking. The beads were washed and aliquoted into a 96-well filter plate (Millipore). 100ul of 4-fold dilution of anti-TSLP antibody was added to triplicate wells, incubated at RT for 0.5 hours, and washed. 100ul of 1:250 dilution of PE-conjugated anti-human IgG Fc (Jackson, #109-116-170) was added to each well, incubated at RT for 0.5 hours, and washed. The beads were resuspended in 75uL, shaken for at least 3 minutes, and incubated in BIOPLEX. TM Read it above.

[0283] A residue was considered to be part of the conformational epitope (a "hit") if mutating the residue to arginine or glutamic acid abolished antibody binding. This was seen as a shift in the EC50 or a reduction in the maximum signal compared to antibody binding to parent TSLP.

[0284] Statistical analysis of parental and mutant antibody binding curves was used to identify statistically significant EC50 shifts, which took into account variability in the assay and curve fitting.

[0285] The EC50 of the mutant and parent binding curves were compared. Statistically significant differences were identified as hits for further consideration. Curves with a "nofit" or "badfit" flag were excluded from this analysis.

[0286] Two sources of variation were considered in comparing EC50 estimates: variation from the curve fit and bead-to-bead variation. Because the parent and mutant were linked to different beads, their differences were complicated by bead-to-bead differences. Curve fit variation was estimated by the standard error of the log EC50 estimate. Bead-to-bead variation was determined experimentally using experiments in which parental controls were linked to one bead each. Bead-to-bead variation was estimated using the bead variation in the EC50 estimate of the parent binding curve.

[0287] Comparison of two EC50s (on a logarithmic scale) was performed using Student's t-test. The t-statistic is calculated as the ratio between δ (the absolute difference between the EC50 estimates) and the standard deviation of δ. The variance of δ is estimated by the sum of three components: the EC50 variance estimates for the mutant and parent curves in the nonlinear regression, and twice the bead-bead variance estimated from separate experiments. The multiple pairwise bead-bead variance results from the assumption that both mutant and parent beads have the same variance.

[0288] The degrees of freedom for the standard deviation of δ were calculated using the Satterthwaite (1946) approximation. Individual p-values ​​and confidence intervals (95% and 99%) were obtained based on the Student's t-distribution for each comparison. In case of multiple parental controls, a conservative approach was implemented by selecting the parental control most similar to the mutant (i.e., the one with the largest p-value).

[0289] During the simultaneous execution of multiple tests, multiplicity adjustment was important to control for false positives. Two forms of multiplicity adjustment were performed for this analysis: family wise error (FWE) control and false discovery rate (FDR) control. The FWE approach controls the probability that one or more hits are not present; the FDR approach controls the expected proportion of false positives among the selected hits. The former approach is more conservative and less powerful than the latter approach. For this analysis, many methods are available for both approaches, and the Hochberg (1988) method was selected for the FWE analysis and the Benjamini-Hochberg (1995) FDR method was selected for the FDR analysis. Corrected p-values ​​for both approaches were calculated either for each antibody or for the entire assay.

[0290] Mutations whose EC50s were significantly different from the parent (i.e., had an FWE-corrected p-value for each antibody less than 0.01 or a maximum signal less than 50% of the parent) were considered to be part of the structural epitope (Table 6). Mutations that were significant either by a shift in EC50 or a reduction in maximum signal for all antibodies were considered misfolded. These mutations were Y15R, T55R, T74R, and A77R.

[0291] [Table 6] There were several mutations (notably K73E, K21E, and D22R) that disrupted binding of multiple antibodies. Mutagenesis helps validate the data generated by binning and further narrows down the epitope space. Mutations within TSLP appear to affect clusters of antibodies that bin together.

[0292] Example 10: Toxicology Antibodies that still bind human TSLP and cross-react with TSLP in other species would allow for toxicology studies in those species. In this example, antibodies that cross-react with cynomolgus TSLP were administered to cynomolgus monkeys. The monkeys were then observed for toxic effects.

[0293] A single-dose safety pharmacology study in cynomolgus monkeys showed that a single 300 mg / kg intravenous dose of the antibody had no cardiovascular, respiratory, thermogenic or neurobehavioral effects.

[0294] Cynomolgus monkeys (5 / sex / group) were given doses of 30, 100 or 300 mg / kg subcutaneously once a week for 4 weeks. No adverse toxicology was observed at any dose. The antibody had no effect on clinical findings, body weight, ophthalmology, ECG, clinical pathology or anatomic pathology.

[0295] In a separate study, four telemeterized cynomolgus monkeys were given a single intravenous dose of vehicle (day 1) and 300 mg / kg of antibody (day 3). No effects on cardiovascular, respiratory, or neurological function were observed over the four-day observation period.

[0296] The antibodies above will be further tested and approved according to the FDA guidelines “Points to Consider” der in the Manufacture and Testing of Monoclonal Antibody Products for Human Use” (FDA Center for Biologics Evaluation and Cross-reactivity with normal human and cynomolgus monkey tissues was determined as recommended in the US Pat. No staining of normal tissues was observed at either 1 ug / mL or 50 ug / mL.

[0297] The above results suggest that this antibody is not expected to produce toxic effects in humans.

Claims

1. below: a. below: i. a light chain CDR3 sequence that differs from a CDR3 sequence selected from the group consisting of light chain CDR3 sequences A1-A27 by a total of no more than two amino acid additions, substitutions and / or deletions; ii. QQAX 8 SFPLT (SEQ ID NO: 251); a light chain CDR3 sequence selected from the group consisting of: b. below: i. a heavy chain CDR3 sequence that differs from a CDR3 sequence selected from the group consisting of heavy chain CDR3 sequences A1-A27 by a total of no more than three amino acid additions, substitutions and / or deletions; ii. GGGIX 12 VADYYX 13 YGMDV (SEQ ID NO: 255); iii. DX 21 GX 22 SGWPLFX 23 Y (SEQ ID NO: 259); a heavy chain CDR3 sequence selected from the group consisting of:

1. An isolated antigen binding protein comprising an amino acid sequence selected from the group consisting of: X 8 is an N or D residue; X 12 is a P or A residue; X 13 is a Y or F residue; X 21 is a G or R residue; X 22 is an S or T residue; X 23 is an A or D residue, and The antigen binding protein specifically binds to TSLP. Antigen-binding proteins.

2. Additionally: a. below: i. a light chain CDR1 sequence that differs from a light chain CDR1 sequence of A1-A27 by no more than three amino acid additions, substitutions and / or deletions; ii. RSSQSLX 1 YSDGX 2 TYLN (SEQ ID NO: 246); iii. RASQX 4 X 5 SSWLA (SEQ ID NO: 249); a light chain CDR1 sequence selected from the group consisting of: b. below: i. a light chain CDR2 sequence that differs from a CDR2 sequence of A1-A27 by no more than two amino acid additions, substitutions and / or deletions; ii. KVSX 3 WDS (SEQ ID NO: 247); iii. X 6 X 7 SSLQS (SEQ ID NO: 250); iv. QDX 9 KRPS (SEQ ID NO: 252); a light chain CDR2 sequence selected from the group consisting of: c. below: i. a heavy chain CDR1 sequence that differs from a CDR1 sequence of A1-A27 by no more than two amino acid additions, substitutions and / or deletions; ii. X 10 YGMH (SEQ ID NO: 253); iii. X 15 X 16 YM.X. 17 (SEQ ID NO: 257); a heavy chain CDR1 sequence selected from the group consisting of: d. below: i. a heavy chain CDR2 sequence that differs from a CDR2 sequence of A1-A27 by no more than 3 amino acid additions, substitutions and / or deletions; ii. VIWX 11 DGSNKYYADSVKG (SEQ ID NO: 254); iii. VISYDGSX 14 KYYADSVKG (SEQ ID NO: 256); iv. WINPNSGGTNX 18 X 19 X 20 KFQG (SEQ ID NO: 258); A heavy chain CDR2 sequence selected from the group consisting of:

2. The isolated antigen binding protein of claim 1, further comprising an amino acid sequence selected from the group consisting of: X 1 is a V or I residue; X 2 is an N or D residue; X 3 is a Y or N residue; X 4 is a G or S residue; X 5 is an L or I residue; X 6 is an N or T residue; X 7 is a T or A residue; X 9 is a K or N residue; X 10 is an S or N residue; X 11 is a Y or F residue; X 14 is a Y or N residue; X 15 is a D or G residue; X 16 is a Y or D residue; X 17 is a Y or H residue; X 18 is a Y or H residue; X 19 is a V or A residue; X 20 is a Q or R residue, and The antigen binding protein specifically binds to TSLP. Antigen-binding proteins.

3. below: a. below: i. a light chain CDR1 sequence selected from A1-A27; ii. a light chain CDR2 sequence selected from A1-A27; iii. a light chain CDR3 sequence selected from A1-A27; or b. below: i. a heavy chain CDR1 sequence selected from A1-A27; ii. a heavy chain CDR2 sequence selected from A1-A27; and iii. a heavy chain CDR3 sequence selected from A1-A27; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b); 2. The isolated antigen binding protein of claim 1 , comprising:

4. below: a. below: i. an amino acid sequence having at least 80% identity to a light chain variable domain sequence selected from L1-L27; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding a light chain variable domain sequence of L1-L27; iii. A sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to a complementary strand of a polynucleotide consisting of the light chain variable domain sequence of L1 to L27; a light chain variable domain sequence selected from the group consisting of: b. below: i. a sequence of amino acids that is at least 80% identical to the heavy chain variable domain sequence of H1-H27 array; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding a heavy chain variable domain sequence of H1-H27; iii. A sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to a complementary strand of a polynucleotide consisting of a heavy chain variable domain sequence of H1 to H27; or a heavy chain variable domain sequence selected from the group consisting of c. a light chain variable domain of (a) and a heavy chain variable domain of (b); 2. The isolated antigen binding protein of claim 1 , comprising either:

5. below: a. a light chain variable domain sequence selected from the group consisting of L1-L27 b. a heavy chain variable domain sequence selected from the group consisting of H1-H27, or c. the light chain variable domain of (a) and the heavy chain variable domain of (b).

1. An isolated antigen binding protein comprising any one of the following:

6. L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13.1H13, L1 3.2H13, L14.1H14, L14.2H14, L15.1H15, L15.2H15, L16.1H16, L16.2H16, L17H17, L18.1H18, L 6. The isolated antigen binding protein of claim 5, comprising a light chain variable domain sequence and a heavy chain variable domain sequence selected from the group consisting of: 18.2H18, L19.1H19, L19.2H19, L20.1H20, L20.2H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26 and L27H27.

7. 6. The isolated antigen binding protein of claim 1 or 5, wherein the binding protein binds to TSLP with substantially the same Kd as a reference antibody selected from the group of antibodies consisting of A2, A3, A4 and A5.

8. 6. The isolated antigen binding protein of claim 1 or 5, wherein the binding protein inhibits TSLP activity with an IC50 identical to that of a reference antibody selected from the group of antibodies consisting of A2, A3, A4 and A5 according to a primary cell OPG assay.

9. 2. The isolated antigen binding protein of claim 1, wherein the antigen binding protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an F(fa')x fragment, a domain antibody, an IgD antibody, an IgE antibody, and an IgM antibody, and an IgG1 antibody, and an IgG2 antibody, and an IgG3 antibody, and an IgG4 antibody, and an IgG4 antibody with at least one mutation in the hinge region that reduces the tendency to form intra-heavy chain disulfide bonds.

10. 2. The isolated antigen binding protein of claim 1, wherein the antigen binding protein is a human antibody.

11. A pharmaceutical composition comprising the antibody of claim 9 or 10.

12. An isolated nucleic acid comprising a polynucleotide sequence encoding the light chain variable domain, the heavy chain variable domain, or both, of the antigen binding agent of claim 5.

13. 13. The isolated nucleic acid of claim 12, wherein the sequence is selected from L1 to L27, H1 to H27, or both.

14. A recombinant expression vector comprising the nucleic acid of claim 12.

15. A host cell comprising the vector of claim 14.

16. A hybridoma capable of producing the antibody according to claim 10.

17. 12. A method for producing the antibody of claim 11, comprising incubating a host cell of claim 15 under conditions that allow the cell to express the antibody.

18. 12. A method of treating a TSLP-associated inflammatory condition in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the composition of claim 11.

19. 19. The method of claim 18, wherein the inflammatory condition is selected from the group consisting of allergic asthma, allergic rhinosinusitis, allergic conjunctivitis, and atopic dermatitis.

20. 12. A method of treating a TSLP-associated fibrotic disorder in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the composition of claim 11.

21. 21. The method of claim 20, wherein the fibrotic disorder is selected from the group consisting of scleroderma, interstitial lung disease, idiopathic pulmonary fibrosis, fibrosis resulting from chronic hepatitis B or chronic hepatitis C, radiation-induced fibrosis and fibrosis resulting from wound healing.

22. An isolated antigen binding protein that cross-competes for binding to TSLP with an antibody selected from the group consisting of A1-A27.

23. 23. The isolated antigen binding protein of claim 22, wherein the antigen binding protein comprises an antibody heavy chain variable region and a light chain variable region.

24. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity greater than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101E and K103E.

25. 25. The isolated antigen binding protein of claim 24, which has a binding affinity for any two or more members of the group of mutated TSLP that is greater than the wild-type affinity.

26. 26. The isolated antigen binding protein of claim 25, which has a binding affinity for all members of the group of mutated TSLP that is greater than the wild-type affinity.

27. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity that is less than the affinity of the wild-type, the group of mutated TSLP being K21E, T25R, S28R, An antigen binding protein comprising a mutated TSLP comprising a mutation selected from the group consisting of S64R and K73E.

28. 28. The isolated antigen binding protein of claim 27, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

29. 29. The isolated antigen binding protein of claim 28, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

30. 28. The isolated antigen binding protein of claim 27, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the wild-type affinity, said second group of mutated TSLP comprising a mutated TSLP comprising a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101E and K103E.

31. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity greater than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of K97E, K98E, R100E, K101E and K103E.

32. 32. The isolated antigen binding protein of claim 31 , which has a binding affinity for any two or more members of the group of mutated TSLP that is greater than the wild-type affinity.

33. 33. The isolated antigen binding protein of claim 32, which has a binding affinity for all members of the group of mutated TSLP that is greater than the wild-type affinity.

34. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of K10E, A14R, K21E, D22R, K73E, K75E and A76R.

35. 35. The isolated antigen binding protein of claim 34, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

36. 36. The isolated antigen binding protein of claim 35, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

37. 35. The isolated antigen binding protein of claim 34, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the wild-type affinity, said second group of mutated TSLP comprising a mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E and K103E.

38. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of K12E, D22R, S40R, R122E, N124E, R125E and K129E.

39. Wild-type affinity for any two or more members of the group of mutated TSLPs 39. The isolated antigen binding protein of claim 38, having a binding affinity lower than

40. 40. The isolated antigen binding protein of claim 39, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

41. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of S40R, S42R, H46R, R122E and K129E.

42. 42. The isolated antigen binding protein of claim 41, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

43. 43. The isolated antigen binding protein of claim 42, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

44. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of D2R, T4R, D7R, S42R, H46R, T49R, E50R, Q112R, R122E, R125E and K129E.

45. 45. The isolated antigen binding protein of claim 44, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

46. 46. ​​The isolated antigen binding protein of claim 45, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

47. 45. The isolated antigen binding protein of claim 44, which binds to a mutated TSLP comprising the mutation K101E with an affinity greater than the wild-type affinity.

48. 1. An isolated antigen binding protein which binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of N5R, S17R, T18R, K21E, D22R, T25R, T33R, H46R, A63R, S64R, A66R, E68R, K73E, K75E, A76R, A92R, T93R, Q94R and A95R.

49. 49. The isolated antigen binding protein of claim 48, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

50. 50. The isolated antigen binding protein of claim 49, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

51. 49. The isolated antigen binding protein of claim 48, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the wild-type affinity, said second group of mutated TSLP comprising a mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E and K103E.

52. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of K21E, K21R, D22R, T25R, T33R, S64R, K73E, K75E, E111R and S114R.

53. 53. The isolated antigen binding protein of claim 52, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

54. 54. The isolated antigen binding protein of claim 53, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

55. 53. The isolated antigen binding protein of claim 52, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the wild-type affinity, said second group of mutated TSLP comprising a mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E and K103E.

56. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of E9R, K10E, K12E, A13R, S17R, S20R, K21E, K21R, K73E, K75E, N124E and R125E.

57. 57. The isolated antigen binding protein of claim 56, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

58. 58. The isolated antigen binding protein of claim 57, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

59. 57. The isolated antigen binding protein of claim 56, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the wild-type affinity, said second group of mutated TSLP comprising a mutated TSLP comprising a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101E and K103E.

60. 1. An isolated antigen binding protein that binds wild-type TSLP with wild-type affinity, wherein the antigen binding protein binds any of a group of mutated TSLP with an affinity lower than the wild-type affinity, the group of mutated TSLP comprising a mutated TSLP that comprises a mutation selected from the group consisting of A14R, K21E, D22R, A63R, S64R, K67E, K73E, A76R, A92R and A95R.

61. 61. The isolated antigen binding protein of claim 60, which has a binding affinity for any two or more members of the group of mutated TSLP that is lower than the wild-type affinity.

62. 62. The isolated antigen binding protein of claim 61, which has a binding affinity for all members of the group of mutated TSLP that is lower than the wild-type affinity.

63. The antigen binding protein binds to any of a second group of mutated TSLP with an affinity greater than the affinity of the wild type, the second group of mutated TSLP comprising K97E, K98E, K99E, K99F, K99G, K99H, K99I ...

61. The isolated antigen binding protein of claim 60, comprising a mutated TSLP comprising a mutation selected from the group consisting of E, R100E, K101E and K103E.